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Genetisk variasjon og toksisitet hos barn med akutt lymfatisk 
leukemi 
Akutt lymfatisk leukemi (ALL) er den vanligste kreftformen hos barn og i Norge får ca. 30-40 
barn ALL hvert år. Behandlingen består av ulike cellegiftkurer gitt over en periode på 2,5 år 
og overlevelsen ligger i dag på ca. 80-85%. Behandlingen medfører mange bivirkninger, bl.a. 
nedsatt immunforsvar og infeksjoner. Av de som ikke overlever sykdommen skyldes ca. 75% 
kreftsykdommen i seg selv, mens 25% skyldes bivirkninger av behandlingen. Sistnevnte 
kalles behandlingsrelatert død (eng.: treatment related death, TRD).  
I denne studien har vi undersøkt forekomst, risikofaktorer og dødsårsaker hos 88 
TRD-tilfeller blant 2700 pasienter med ALL i de fem nordiske landene Sverige, Danmark, 
Finland, Island og Norge. Vi fant at forekomsten av TRD var på 3,2% og at kjønn (pike), 
behandlingsrisikogruppe (høy-risk), T-celle sykdom, Down syndrom og gjennomgått 
beinmargstransplantasjon var risikofaktorer for TRD. Av dødsårsaker skyldtes 75% 
infeksjoner, 10% blødninger, 10% spesifikk organsvikt og 5% direkte kreftcelle-påvirkning 
(tumor byrde).  
Vi har ingen god forklaring på hvorfor noen pasienter får flere og mer alvorlige 
infeksjoner enn andre. Det er grunn til å tro at genetiske faktorer spiller inn. Vi ville derfor 
undersøke om ulike mønstre av en vanlig forekommende variasjon i det menneskelige genom, 
nemlig enkeltnukleotidpolymorfisme (eng.: single nucleotide polymorphism, SNP) kunne 
spille en rolle for risiko for infeksjoner. Vi undersøkte 34000 SNP’er relatert til ALL hos barn 
og identifiserte en SNP-profil som med stor nøyaktighet kunne forutsi risiko for infeksjoner 
de første 50 dagene av behandlingen. Hvis disse funnene blir bekreftet i tilsvarende studier vil 
denne kunnskapen kunne brukes til å «skreddersy» behandlingen til enkeltpasienter og 
dermed redusere alvorlige bivirkninger.  
I moderne genanalyser inngår ofte mange genvarianter samtidig. Det benyttes som 
regel DNA fra blodprøver, noe som kan være vanskelig å få tak i fra pasienter som ikke 
lenger er i live. Vi ville undersøke om det i stedet var mulig å gjøre genanalyser på 
arkivmateriale fra leukemipasienter, dvs. beinmargsutstryk og –biopsier. To typer markører 
ble undersøkt, 10 såkalte korte tandem repetisjoner (eng: short tandem repeats, STRs) og 
34000 SNP’er. Resultatene ble sammenliknet med tilsvarende analyser på blodprøver og vi 
fant at 90% av STR-markørene lot seg gjenskape. For SNP-analysene fikk vi tilfredsstillende 
resultat for bare 7 av 34 prøver, men to av prøvene ga svært godt resultat. Dette illustrerer at 
bruk av gamle beinmargsprøver til genanalyser er mulig, men at metoden må forbedres.  
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 leukaemia [Gr. leukos, white, + 
haima, blood]. The tube to the 
left is a blood sample from a 
healthy person. The tube to the 
right shows a fresh taken blood 
sample from a boy newly 
diagnosed with acute 
lymphoblastic leukaemia with 
very high white blood cell 
count. The middle “milky” layer 
in the tube shows concentrated 
white blood cells (blast 
cells/cancer cells) illustrating
the term ‘white blood’.
(Photo by the author)
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Definitions and key concepts 
Acute lymphoblastic leukaemia (ALL): a cancer of white blood cells caused by genetic 
alterations of unknown origin leading to uncontrolled cell proliferation at a certain stage of 
maturation of the lymphoblasts. 
Culture positive: the isolation of a microorganism from blood.  
Gene library: a stored collection of DNA fragments ready for further processing 
(sequencing); in our study, the library was prepared from the patient’s genomic DNA and 
includes the SNP-containing DNA fragments. 
Genetics: the science of genes, heredity and variation in living organisms. 
Genomics: a discipline of genetics that applies DNA sequencing methods and bioinformatics 
to sequence and analyse the function and structure of the genome (the complete set of DNA 
within a single cell of an organism).
“Infectious event”: the combination of fever or other signs of infection and initiation of 
antimicrobial therapy after the initiation of anti-leukaemic therapy. 
Metabolic pathway: a series of chemical reactions within a cell often catalysed by enzymes. 
Neutropenia: absolute neutrophil count of  <0.5 × 109/L. 
Remission: a state in which the vast majority of malignant blast cells have been removed 
from the patient by induction treatment, usually when the number of malignant blast cells in 
the bone marrow is <10-3 cellsȝ/
Remission induction treatment: the period of treatment (with chemotherapy, 
glucocorticoids and supportive care) from the point of diagnosis to the time that remission is 
achieved.
Single nucleotide polymorphism: a phenomenon present at various frequencies throughout 
the DNA molecule involving variation in a single nucleotide (A, T, C or G).   
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Sammendrag på norsk 
Kreft er den vanligste medisinske dødsårsaken hos barn mellom 1 og 15 år. Akutt lymfatisk 
leukemi (ALL) er den vanligste kreftformen hos barn og i Norge får ca. 30-40 barn ALL hvert 
år. Behandlingen strekker seg over 2,5 år og består av 6-12 ulike cellegifter i forskjellige 
kombinasjoner i tillegg til støttebehandling og overvåkning. Behandlingen medfører mange 
bivirkninger, bl.a. nedsatt immunforsvar som gir økt risiko for infeksjoner. Den totale 
overlevelsen for barn med ALL er i dag på ca. 80-85%. Av de som dør etter å ha fått 
diagnosen skyldes dette for ca. 75% kreftsykdommen i seg selv hvorav de fleste skjer etter 
tilbakefall av sykdommen (residiv-relaterte dødsfall). De resterende 25% av dødsfallene 
skyldes bivirkninger av behandlingen, noe som kalles behandlingsrelatert død (TRD, 
treatment-related death). 
I denne studien har vi undersøkt forekomst, risikofaktorer og dødsårsaker hos 88 
TRD-tilfeller blant 2700 pasienter med ALL i de fem nordiske landene Sverige, Danmark, 
Finland, Island og Norge. Forekomsten av TRD var 3,2% og denne holdt seg uendret fra den
første ALL protokollen (NOPHO ALL 1992) til den neste (NOPHO ALL 2000). 
Risikofaktorer var kjønn (pike), behandlings-risikogruppe (høy-risk), T-celle sykdom, Down 
syndrom og gjennomgått beinmargstransplantasjon. Av dødsårsaker skyldtes 75% 
infeksjoner, 10% blødninger, 10% spesifikk organsvikt og 5% direkte kreftcelle-påvirkning 
(tumor byrde). 
Vi har ingen god forklaring på hvorfor noen blir mer syke av behandlingen enn andre. 
Det er derfor grunn til å tro at genetiske faktorer spiller inn. I de siste 10 årene har man 
forstått vesentlig mer om den naturlige genetiske variasjon hos menneske. Vi ville undersøke 
om ulike mønstre av en vanlig forekommende variasjon i det menneskelige genom, nemlig 
enkeltnukleotidpolymorfisme (eng.: single nuclotide polymorphism, SNP) kunne spille en 
rolle for risiko for alvorlige infeksjoner under leukemibehandlingen. Vi undersøkte 34000 
SNP’er relatert til ALL sykdommen hos barn og fant 24 SNP’er som var assosiert til risiko for 
infeksjon under behandlingen. Ved hjelp av CART-analyse (classification and regression 
tree) identifiserte vi 4 SNP’er som inngikk i en SNP-profil som var i stand til å forutsi risiko 
for infeksjoner de første 50 dagene av behandlingen med stor nøyaktighet. SNP’ene tilhører 
genene OR51F1, CBR1, POLDIP3 og CCL11 som bl.a. regulerer cellegiftomsetning,
cellevekst og betennelsesreaksjoner. Hvis disse funnene blir bekreftet i tilsvarende studier vil 
denne kunnskapen kunne brukes til bedre å «skreddersy» behandlingen til enkeltpasienter og
dermed redusere forekomsten av alvorlige bivirkninger.  
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I moderne genanalyser inngår ofte mange genvarianter samtidig. Det benyttes som 
regel DNA fra blodprøver, noe som kan være vanskelig å få tak i fra pasienter som ikke 
lenger er i live. Vi ønsket derfor å undersøke om det var mulig å analysere biologiske 
markører på arkivmateriale fra leukemipasienter, dvs. beinmargsutstryk og -biopsier. DNA
ble ekstrahert fra beinmargsprøvene og deretter kvantitert. Pga. små mengder DNA fra hver 
pasientprøve ble det gjort hel-genom amplifisering (whole genome amplification, WGA) som 
et forsøk på å øke DNA mengden i prøvene. Deretter ble prøvene analysert for to typer gen-
markører, 10 såkalte korte tandem repetisjoner (eng.: short tandem repeats, STRs) og 34000 
SNP’er. Resultatene ble sammenliknet med tilsvarende markørundersøkelser på blod og vi 
fant at 90% av STR-markørene lot seg gjenskape fra arkivmaterialet. For SNP-markørene fikk 
vi tilfredsstillende resultat for bare 7 av 34 prøver, men to av prøvene ga svært godt resultat. 
WGA fungerte ganske bra for noen av prøvene, men dårligere sammenliknet med prøver uten 
WGA. Konklusjonen ble at bruk av gamle beinmargsprøver til multiple genanalyser er mulig, 
men analysemetoden må forbedres.  
 
 
Summary in English 
Cancer remains the leading cause of disease-related mortality among children aged 1-14 years
in developed countries. Acute lymphoblastic leukaemia (ALL) is the most common 
malignancy in childhood and accounts for about 25% of all childhood cancers. In Norway 
about 30-40 children are diagnosed with ALL each year. Treatment comprises of a 
combination of 6-12 different chemotherapy drugs administered over a period of 2.5 years
with additional supportive care. Side effects remain a great challenge for both patients and
physicians. One of the most common side effects is immunosuppression which increases the 
risk of infection.  
Today, the overall survival rate in childhood ALL is 80-85%. About 75% of deaths 
related to ALL are caused by the disease itself, most after relapse, but about 25% of deaths are 
caused by treatment and are classified as treatment-related deaths (TRDs).  
In this study, the incidence, risk factors and causes of death were investigated for 88 
TRDs among 2,700 patients in the Nordic countries Sweden, Denmark, Finland, Iceland and 
Norway. The incidence of TRD was 3.2%, which was stable in the two protocols, the Nordic 
Society of Paediatric Haematology and Oncology (NOPHO) ALL 1992 and ALL 2000 
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protocols. The risk factors identified were female gender, treatment risk-group, T-cell disease, 
Down syndrome and stem cell transplantation. Seventy-five percent of the deaths were related 
to infection, 10% to bleeding or thrombosis, 10% to organ failure and 5% to the tumour 
burden. 
We have no good explanation as to why some patients experience more severe 
infections than others, even when receiving the same drugs, drug dosage and supportive care. 
It is reasonable to believe that genetic factors play a role. In accordance with the increasing 
understanding of host genetic variation the past 10 years, we investigated 34,000 single 
nucleotide polymorphisms (SNPs) relevant in childhood ALL in a Danish ALL cohort 
including 69 children and detected 24 SNPs which associated with infections during induction 
treatment. Through CART-analysis (classification and regression tree) a four-SNP risk 
profile were identified as highly predictive of risk of infections during the 50 days induction 
treatment. The four SNPs belong to the genes R51F1, CBR1, POLDIP3 and CCL11 which
regulate drug metabolism, cell-growth and inflammation. If these findings are replicated in 
larger studies, such knowledge may be useful for developing personalized medicine with 
more tailored therapy and supportive care, which will hopefully reduce the severity of side 
effects and increase overall survival.  
Studies involving multiple biological markers, such as SNPs and short tandem repeats 
(STRs), often use high-quality DNA extracted from blood samples. However, blood samples 
are not always easy to obtain from study participants, especially if the patient has died.
Archival bone marrow samples from patients with leukaemia are available and represent a 
potential DNA source. We were interested in exploring whether such archival material is 
usable for the analysis and identification of multiple markers. DNA from 21 bone marrow 
smears and 13 bone marrow biopsies were extracted and quantified. Because of small 
amounts of DNA from each sample whole genome amplification (WGA) was applied. Ten 
different STR-markers and 34,000 SNPs were analysed and compared with corresponding 
blood samples. For the STR markers 90% detection rates were obtained. Shorter markers 
(107bp-242bp) from samples stored 0-3 years gave better results compared with longer 
markers (219bp-317bp) stored 4-10 years. Multiple SNP analysis was more complicated and 
only seven of 34 archival samples gave acceptable results (SNP call-rates above 50%). 
However, in two samples, nearly 100% of SNP-markers were detected. Although increasing 
the total amount of DNA, WGA reduced the analysis quality. In conclusion, DNA from 
archival bone-marrow samples might be used in multiple marker analysis, but adjustments of 
the laboratory set-up are essential to optimize this method.
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INTRODUCTION 
Topic of the thesis 
This thesis examines treatment-related death (TRD) and treatment-related infections in Nordic 
patients with childhood acute lymphoblastic leukaemia (ALL). Clinical risk factors, host 
genome variation, metabolic pathways, and use of archival samples for DNA extraction and
multiple biomarker analysis are explored.  
Perspective and rationale 
Side effects from cancer treatment are daily challenges for patients and clinicians. Severe side 
effects such as infection, occasionally leading to TRDs, represent the most tragic outcome of 
therapy-induced toxicity, especially for childhood ALL treatment. Increased understanding of 
risk factors, included the possible contributions of host genetic factors, is the first step 
towards decreasing the occurrence of such severe events. The role of host genomic variation 
and treatment-related side effects has not been explored fully for childhood ALL. In our 
modern high-throughput sequencing era, the use of different DNA-sources, such as blood 
samples, tissues and smears, has great potential in studies of host genomic variation. Blood 
samples can be difficult to collect in some situations, for instance from patients who have 
died. Alternative samples from such patients are archival samples collected earlier as part of 
the hospital’s routine. For leukaemia patients, bone marrow smears and biopsies represent a 
potential DNA source for such studies.   
We conducted this study on TRDs and infections during treatment by integrating 
clinical and genetic information. We aimed to understand more deeply the causes and risks of 
treatment-related infections and TRDs. Bone marrow archival samples were also tested to 
determine the suitability of DNA extraction and marker-analysis.
The study is organized in three parts. Study I was a clinical study of the risk factors 
and causes of death in 88 TRDs among 2,735 Nordic childhood ALL patients treated between 
1992 and 2008; the data were from the Nordic Society of Paediatric Haematology and 
Oncology (NOPHO) registry. Study II combined clinical data on infections during ALL 
induction treatment with multiple SNP data including 34,000 SNPs aiming at identifying
genetic risk profiles and relevant metabolic pathways related to infections during treatment. 
Study III was a methodological study exploring the challenges involved in using DNA
derived from archival bone marrow samples from childhood ALL patients in multiple 
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biomarker analysis. These studies are referred to as the paper produced from the data in the 
study: Papers I, II and III, respectively.   
Theory and central concepts 
Acute lymphoblastic leukaemia 
Cancer remains the leading cause of disease-related mortality in developed countries among 
children aged 1-14 years (Ghaderi et al., 2012; "Statistics Norway [Internet] Available from: 
https://www.ssb.no,"). ALL is the most common malignancy in childhood, accounting for 
about 25% of all childhood cancers (Kaatsch, 2010). ALL is a cancer of the white blood cells
(WBC) of unknown origin. The disease develops as a consequence of malignant 
transformation of a single abnormal lymphoid precursor cell leading to uncontrolled 
proliferation and expansion in the bone marrow and other lymphoid organs. In the 1950s, 
childhood ALL was considered an incurable disease. During the past few decades, there has 
been a steady increase in both event-free survival (EFS) and overall survival (OS); 75% of all 
patients are now cured by first-line therapy, and there is a long-term survival rate of about 
83% (Fig. 1) (Schmiegelow et al., 2010).  
Figure 1. Overall survival in four consecutive Nordic Society of Paediatric Haematology and 
Oncology (NOPHO) cohort periods (4). Number of patients in the respective protocols, 
NOPHO1982-1985: n1=719; 1986-1991: n2=937; 1992-2001: n3=1,645; and 2002-2007: 
n4=1,023
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ALL is diagnosed by the presence of more than 25% lymphoblast cells in the bone 
marrow recognized by microscopic examination of Giemsa-stained bone marrow smears and 
flow cytometric techniques. Treatment comprises metronomic administration of 6-12 different 
chemotherapeutic agents for 2.5 years from the time of diagnosis. For patients with very high 
relapse risk, haematopoietic stem cell transplantation (HSCT) is the only treatment option 
providing a chance of a cure. Chemotherapy treatment implies side effects, and intensive 
treatment requires intensive supportive care. Treatment-related toxicity is a great challenge 
for both patients and clinicians, and TRD is the most severe side effect (Blanco et al., 2012;
Prucker et al., 2009; Rahiala et al., 1998). Short- and long-term side effects play a crucial role 
in determining the patient’s quality of life both during and after treatment. Examples of side 
effects are infections, bleeding, thrombosis, cardiovascular and pulmonary problems, 
neurological impairment, nutritional problems, osteonecrosis, fatigue and secondary 
malignancies. In addition, the risk of relapse is always present during treatment and the years 
following treatment. 
The events contributing to reduced EFS are resistant disease (1.0%), relapse (16.9%), 
TRD (3.2%), and secondary malignant neoplasms (SMNs) (1%). Factors influencing these 
events are: i) the malignant lymphoblastic clone with its intrinsic genetic and chromosomal 
rearrangements; ii) anti-leukaemic treatment including chemotherapy and glucocorticoids 
(GCs); iii) supportive care (e.g., monitoring/nursing, fluids, nutrition, antibiotics, anti-
thrombotics and procedures); and iv) host factors (e.g., host genetics and host environment). 
The most crucial treatment period is the first weeks and months after diagnosis because the 
malignant clone is still present (first days/weeks) and may infiltrate into the bone marrow, 
leading to neutropenia, lymphopenia, anaemia and thrombocytopenia, which increases the 
risk of bleeding and infections. The malignant cells can also infiltrate into other vital organs, 
thus increasing the risk of leukostasis. In addition, initiation of chemotherapy and GCs
(prednisolone/dexamethasone) leads to immunosuppression, risk of bleeding and problems 
related to tumour-lysis (e.g., renal failure).  
Treatment-related death 
Despite improved supportive care, 2-4 % of patients die because of treatment-related causes.
The risk of TRD has not decreased substantially in the past 20 years (Blanco et al., 2012; M. 
S. Christensen et al., 2005; Hill et al., 2004; Prucker et al., 2009; Rubnitz et al., 2004) and 
TRDs contributes to reduced outcomes of cancer treatment in general. Normally, a TRD is 
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regarded as a death during treatment, and in some studies, the term also includes death
occurring a short time after the end of treatment. Death many years after the end of treatment
that is related to late effects after cancer treatment is not normally regarded as a TRD.
In parallel with the decreasing number of patients dying from the leukaemia itself (i.e.,
tumour burden-related death, resistant disease or relapse), TRDs seem to comprise an 
increasing proportion of overall mortality because the TRD rate seems to be unchanged 
(Blanco et al., 2012). In both the NOPHO ALL-1992 and ALL -2000 protocols, TRDs 
accounted for 25% of all deaths (Fig. 2). One possible explanation for the stable TRD-rate is 
that the reduction in relapse rates by increased treatment intensity for high-risk patients has 
led to a higher risk of TRD. An increased focus on supportive care (i.e., more adequate 
antibiotics, better treatment of tumour-lysis and more awareness of side effects in general), 
may have balanced this increased toxicity, thus producing stable TRD rates. Thus, as the 
proportion of deaths attributed to TRDs has increased, the focus on severe toxic events has 
become increasingly important.
Figure 2. Causes of death in NOPHO ALL-1992 and ALL-2000 protocols. SMN, second 
malignant neoplasm; Res Dis, resistant disease; TRDs, treatment-related deaths (data from 
NOPHO ALL registry)
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Definition of TRD 
There is no internationally accepted definition of TRD (also referred to as toxic death,
treatment-related mortality or non-relapse mortality). In clinical trials, a death during therapy 
is reported as a serious adverse event, which is defined as any undesirable experience 
associated with the use of a medical product in a patient, and includes (among others) death, 
life-threatening event, hospitalization (initial or prolonged), disability or permanent damage. 
This term also includes non-fatal events and is mostly used in studies of new drugs (Choueiri 
et al., 2013; "U.S. Food and Drug Administration [Internet] Available from: 
http://www.fda.gov,"). Another term is suspected unexpected severe adverse reaction. Within 
the field of paediatric oncology, most authors include as TRDs those events related to a 
certain drug or drug combinations, as well as those related to the total therapy given, namely 
chemotherapy, supportive care and procedures (HSCT, surgery, cardiopulmonary support, 
etc.).  
Many authors define TRD differently, as reported by Ethier and co-workers (Ethier et 
al., 2011). Some authors relate TRD to the phase of therapy during which the event occurred 
(e.g., induction, consolidation or maintenance treatment). Others relate TRD to specific time 
sets after the start of therapy. TRDs after HSCT, early deaths (i.e., after diagnosis, but before 
treatment) and deaths happening soon after the end of treatment (but obviously related to 
treatment) are sometimes included, but sometimes not. Authors do not necessarily present the 
overall toxicity-related death rate over the course of treatment when presenting protocol 
results and, because of the variability in the definition, TRD-rates can be difficult to interpret 
and may not be comparable between studies (Ethier et al., 2011).   
Causes of TRDs - attribution
Another problem with reporting TRDs is attribution or the cause of death. An internationally
acceptable definition or a system for attribution does not exist. Authors use different 
definitions of infection-related mortality (M. S. Christensen et al., 2005; Slats et al., 2005). 
There is no definition of the type or extension of haemorrhage that constitutes a bleeding 
related death. Patients might have multiple concurrent serious events close to death (e.g., 
organ dysfunction, infection and haemorrhage), complicating the identification of the primary 
cause of death. Ethier and co-workers (Ethier et al., 2011) proposed the following:  
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x A system is needed to categorize the certainty of attribution as definite, probable or 
possible. 
x In cases with multiple causes of death, all possible causes of death along with the 
associated certainty of attribution should be listed.  
These proposed standards would make it easier to compare results between treatment 
protocols.  
In Paper I, TRD-patients were grouped by cause of death into five categories as 
follows: i) tumour burden-related, ii) bleeding or thrombosis, iii) infection, iv) organ toxicity 
and v) other or uncertain cause. This grouping was an attempt to increase our understanding 
of the cause of death, even though we realize that such grouping is complicated. However, our 
study collected detailed clinical information on the causes of death (Appendix), including 
autopsy reports for some patients, and we believe this information is meaningful. An 
additional problem is a death by multiple causes. When in doubt, cases included in our study 
were discussed within the NOPHO Events Group as an attempt to clarify the probable chain 
of events leading to death, with special emphasis on the most important initiating factor. An 
example is a patient with Pseudomonas-sepsis who suddenly deteriorates, is put on a
ventilator and, secondary to the infection, exhibits severe coagulation disturbances which lead 
to a fatal brain haemorrhage. In this case, we considered the Pseudomonas infection as the 
most important initial event and coagulation disturbances as the contributing cause. This case 
was classified as an infectious TRD. 
Infections and inflammation during treatment 
Infections are one of the most common side effects of treatment (Afzal et al., 2009; Rahiala et 
al., 1998; Rungoe et al., 2010). Infections can be life-threatening and are the most common 
cause of TRD (Study I) (M. S. Christensen et al., 2005; Prucker et al., 2009). The clinical 
spectrum of symptoms and signs of infection/inflammation during treatment spans from mild 
symptoms of low-grade fever but otherwise no symptoms to severe life-threatening infections 
requiring cardiopulmonary support. A widely used clinical entity is the condition termed 
“febrile neutropenia” which happens to all patients several times during treatment (Stabell et 
al., 2008). This occurs when the patient displays neutropenia (i.e., absolute neutrophil count 
(ANC) <0.5 × 109/L) and the body temperature is >38.0-38.5 °C.  
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When a patient experiences febrile neutropenia, most treatment centres start routinely 
with empirical broad-spectrum antibiotics. The patient is monitored closely and, if fever 
disappears and no other signs develop, antibiotics are terminated after 3-5 days or are given 
until the patient is no longer neutropenic and is otherwise in good condition. In other cases, 
the initial mild symptoms develop into a more severe episode with fulminant sepsis.
Sometimes febrile neutropenia is caused by an infection. In other situations, febrile 
neutropenia probably represents a state of inflammation without infection, giving rise to fever. 
A documented infectious focus and/or a microbiological organism is detected in 20-
40% of patients with a suspected infectious episode in studies of childhood leukaemia 
(Bakhshi et al., 2008; Graubner et al., 2008; Lehrnbecher et al., 2004). The type of infective 
organism ranges from common Gram-positive and Gram-negative bacteria to microorganisms 
found more often in immunosuppressed patients (e.g., Pseudomonas species, fungi,
Pneumocystis jiroveci). Sometimes these episodes lead to death (infectious TRD). From a 
clinical point of view, it cannot be predicted which patients will experience the most severe 
infectious episodes because patients within the same risk group (i.e., same treatment intensity) 
and of the same age/gender may have a completely different “infectious profile” throughout 
treatment. Some patients will develop mild and few infectious episodes, whereas others will 
develop more severe infectious episodes. This clinical observation leads to the idea that, in 
addition to known risk factors and incidental differences between individuals, the host genetic 
profile might contribute to greater phenotypic variation. Childhood ALL patients are 
immunocompromised by the disease and chemotherapy given. Additionally comes, for young 
children, an immature immune system. Thus, the host genomic profile relating to innate 
immunity and pharmacogenetics might play a more important role in the response to an 
infectious episode in ALL patients compared with non-immunocompromised and otherwise 
healthy individuals.  
Infections are complex diseases in which the outcomes depend on the interaction 
between the host’s genetic make-up and the environment. Important environmental factors are
i) the type of infectious microorganism, ii) antibiotic susceptibility, iii) the site of infection, 
iv) how soon the infection is detected, v) appropriate antibiotic treatment and vi) supportive 
care (resuscitation, supportive medical management and/or surgery) (Huttunen et al., 2011;
Sutherland et al., 2009). The effect of the host’s genetic make-up may also be modified by 
environmental factors.  
The pathogenesis of sepsis includes the involvement of inflammatory cells and 
signalling molecules, and the balance between the pro- and anti-inflammatory states. This 
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Host genome variation 
In genetic studies of leukaemia, research has focused on genetic alterations in leukaemic blast 
cells to understand the disease aetiology and pathogenesis (Mullighan, 2012). Less attention 
has focused on host genomics and its influence on outcomes. Host DNA sequence variation 
influences many aspects of a person’s characteristics including anthropometry, risk of disease, 
drug metabolism and other environmental responses (Sachidanandam et al., 2001). Examples 
of host genome variation are SNPs, copy-number variation, repeating elements
(microsatellites, short tandem repeats (STRs), minisatellites) and inversions. A SNP is a
single nucleotide variation present at various positions throughout the DNA molecule. This 
phenomenon occurs when a single nucleobase (A,T,C or G) at a specific position in the DNA 
strand is substituted with another nucleobase. In Fig. 4, thymine (T) in Allele 1 is substituted 
with cytosine (C) in Allele 2. The most prevalent allele in the population is termed the wild-
type allele, and the less prevalent allele is termed the variant allele. Individuals can have two 
copies of either the wild-type or the variant allele, called homozygous, or can have one copy 
each of the wild-type and variant allele, called heterozygous. Most SNPs are bi-allelic. SNPs 
occur at certain frequencies in different populations and can be assigned a minor allele 
frequency (MAF) in a population, i.e., the frequency of the variant allele.
Figure 4. Single nucleotide polymorphism. In Allele 2, a T is substituted with a C in the 
corresponding position as in Allele 1. The nucleobases in double-stranded DNA are 
complementary so that T (thymine) always binds to A (adenine) and C (cytosine) always 
binds to G (guanine). 
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SNPs are highly frequent. About one SNP occurs per 300-1,000 base pairs (K. 
Christensen et al., 2007; Sachidanandam et al., 2001), meaning that up to 10 million SNPs are
situated in the 3 billion base-pairs in the entire human genome. SNPs can be located in exons, 
introns or close (promoter) or remote regulatory (enhancer) regions in the DNA. In exons, 
they can be synonymous (i.e., they do not affect the amino-acid sequence in the protein) or 
non-synonymous. Non-synonymous SNPs give rise to changes in the amino-acid composition 
of the corresponding protein. Since the first publication of the entire sequence of the human 
genome in 2001 (Consortium, 2004; Sachidanandam et al., 2001), much attention has focused 
on linking phenotypical traits (e.g., diseases, disease risk factors, enzymes, drug metabolism) 
with human genetic variants including SNPs. It is important to recognize that the association 
of one or more SNPs with a certain trait or phenotype does not necessarily explain the 
causality of the underlying biological mechanism. The associated SNP can be causal, but it 
can also be a “tag-SNP” in linkage disequilibrium with the causative SNP because gene 
fragments are inherited as haplotypes.  
An example of a known clinically relevant SNP used in treatment of childhood ALL is 
genetic variation in the TPMT-gene. 6-Mercaptopurine (6-MP) has been used for many years 
in the treatment of childhood ALL and is one of the main drugs used during maintenance 
therapy in most protocols. 6-MP is metabolized by thiopurine methyltransferase (TPMT), an 
enzyme encoded by the TPMT-gene. This enzyme is affected by functional SNPs in the 
TPMT-gene that reduce the activity of the enzyme (Schmiegelow et al., 2009). A consequence 
for heterozygous or homozygous (variant allele) patients is that reduced 6-MP metabolism
because of reduced TPMT activity can increase drug toxicity and cause prolonged 
neutropenia, which increases the risk of infections. Consequently, the dose of 6-MP is 
reduced for such patients. TPMT-SNP-genotyping is performed routinely in many 
contemporary ALL protocols including the NOPHO ALL-2008 protocol.  
STRs or microsatellites are small DNA elements comprising one-, two-, or three-base 
sequences repeated in tandem 15-100 times. STR loci often mutate into multiple alleles and 
are highly polymorphic in the number of repeats. They are stable, highly polymorphic DNA 
markers often used in family studies, in forensic medicine and in paternity testing. In our 
studies both multiple SNPs and STRs were included as biological markers. 
Multifactorial traits such as infection are considered to be affected by multiple 
underlying causal pathways (Huttunen et al., 2011; Sutherland et al., 2009). These pathways 
include gene regulation from single genes to protein formation through transcription, 
translation, protein stability, RNA interference, DNA methylation, and other cellular events. 
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Based on this complex nature of several important disease traits, including the multifaceted 
interplay of genes and proteins, multiple genetic studies often focus on pathways, gene-
networks and gene-gene interactions. 
Genome-wide association studies (GWASs) have been useful in many studies 
(Andersson et al., 2009; Yang et al., 2009). Using this technique, one can study several SNPs 
at a time (0.5-1 million) in a single run, and newly identified genes or SNPs can be linked to a 
phenotype. A common limitation of GWAS design is the microchip-based design with a fixed 
SNP set-up and low flexibility. Additionally, most SNPs are located outside known genes. If a 
specific SNP is associated with a certain trait, interpreting the underlying biological 
mechanism is complicated. Another approach is single-SNP or single-candidate gene-
association studies. The benefit of such studies is that the function of the candidate gene is
known, but the obvious limitation is identifying the pathway to be studied.  
Genetic variation and infections in childhood acute lymphoblastic 
leukaemia 
Host genomic variation and risk of infections have been investigated in many groups of 
patients, including children and childhood cancer patients. One important question is whether 
immunocompromised childhood ALL patients have the same genetic risk profile regarding 
severity of an infectious episode as non-immunocompromised patients. The outcomes of 
infection depend on many factors to which the genetic contribution probably varies. The 
infective microorganism’s susceptibility to the antibiotics used probably contributes more to 
the risk of severe outcome compared with the involvement of a specific SNP; for instance, in 
innate immunity in an otherwise healthy child. However, many genetic polymorphisms that 
are significantly associated with more severe outcomes of infection have been found. Selected 
studies, including some studies on children with leukaemia, are listed in Table I. The studies 
in Table I show only a few SNPs or other genetic variations associated with infection. Few 
studies have investigated multiple biomarkers related to infection or the metabolic pathways 
of importance for determining the outcome of infection.  
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Gene/protein Disease Population Year Ref. 
Complement factor H Y402H, 
MBL2, PAI-1, CFB, C1qA 
SIRS, sepsis Children 2010 (Agbeko et 
al., 2010) 
TNF-ɲ͕LT-ɲ Lethal infection, 
ALL 
Children 2009 (Kidas et al., 
2009) 
IL7Rɲ Outcome HSCT Children/ 
adults 
2006 (Shamim et 
al., 2006) 
TLR2/4/5, CD14, MBL, IRAK4, 
TNF-ɲ, MIF, IL-10, IL-6, IL-
1RA 
Sepsis (many 
microorganisms) 
Children/ 
adults 
2005 (Arcaroli et 
al., 2005) 
(review) 
IL6, CHIT G-negative 
bacteria, AML 
Children 2005 (Lehrnbecher 
et al., 2005) 
MBL Infections, ALL Children 2005 (Lausen et 
al., 2006) 
IL10 promoter 
(TNF, LT-ɲͿ 
Pneumococcus, 
septic shock 
adults 2003 (Schaaf et 
al., 2003) 
IL-12, IL-12R, IFN-ɶ, IFN-ɶR, 
STAT1 
Mycobacteria, 
Salmonella 
Children/ 
adults 
2002 (Ottenhoff et 
al., 2002) 
(review) 
TLR4 G-negative 
infections 
Adults 2002 (Agnese et 
al., 2002) 
TNF2 (TNFɲ-ƉƌŽŵŽƚĞƌͿ Septic shock, 
mortality 
Adults 1999 (Mira et al., 
1999) 
Table I: Selected reports on genetic polymorphisms affecting the outcomes of infections for 
children and adult cancer and non-cancer patients. MBL, mannose-binding lectin; PAI-1,
plasminogen activator inhibitor-1; CFB, complement factor B; C1QA, complement C1q 
subcomponent subunit A; TNF, tumour necrosis factor; LT, leukotriene; IL, interleukin; TLR, 
toll-like receptor; CD, cluster of differentiation; IRAK, interleukin receptor-associated kinase; 
MIF, macrophage migration inhibitory factor; CHIT, chitotriosidase; AML, acute 
lymphoblastic leukaemia; STAT, signal transducer and activator of transcription; SIRS, 
systemic inflammatory response syndrome; HSCT, haematopoietic stem cell transplantation.
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Biological samples for genetic studies 
Multiple genetic association studies normally depend on high-quality DNA stored in 
biobanks. Considering the clinical risk factors for TRD identified in Study I, we were 
interested in including host genomic variations of possible relevance to infectious TRD in our 
studies. Unfortunately, there was no systematic biobanking of blood samples from the TRD 
patients, and the question was raised whether other DNA-sources could be used for further 
genetic studies. Archival samples, such as biopsy specimens, cytology and haematology
smears, have been used in studies of genetic biomarkers for decades (Boyle et al., 1998;
Kanteti et al., 2009; Lausten-Thomsen et al., 2010; Srinivasan et al., 2002; Stanulla et al., 
2000; Thompson et al., 2005; Aaltonen et al., 2011). However, poor DNA yield and structural 
changes such as degradation and mutations may influence the results of both DNA 
sequencing and comprehensive marker analysis. Known factors contributing to possible poor 
DNA-quality are sample age, storage, and the fixation and staining methods (Falconi et al., 
2007; Foss et al., 1994; Gilbert et al., 2007).  In childhood ALL, bone marrow smears and 
biopsies are taken at diagnosis and several times during treatment, and these are stored for 
many years as part of the hospital’s archival routines. Thus, there are often surplus samples 
representing a potential biobank and a possible means for obtaining DNA from the patients 
whose deaths are considered infectious TRDs. Unfortunately, there was no established 
method for multiple SNP sequencing based on DNA from such archival material, and the 
quality of such DNA was uncertain. We therefore wanted to test this in a separate study. Our 
research group has worked with a multiple SNP sequencing platform in other studies, and it 
was therefore natural to apply this SNP platform to the archival material. We also wanted to 
test the archival samples for other kinds of markers, and we selected an STR marker kit used 
routinely in our laboratory. 
Poor DNA yield from archival samples may be an obstacle to multiple marker 
sequencing, and the techniques for DNA amplification are of interest. Whole-genome 
amplification (WGA) by multiple displacement amplification has been developed as a method 
for increasing the DNA content of a sample while keeping the sequence representation of the 
template intact (Spits et al., 2006). In a recently published study, our research group was 
successful in applying WGA to DNA from archival bone marrow samples (Lausten-Thomsen 
et al., 2010). Thus, we thought that WGA might represent a potential solution to the problem 
of poor DNA yield in our study.  
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Nordic Society of Paediatric Haematology and Oncology collaboration 
NOPHO was established in 1981 in an effort to introduce uniformity in the treatment of
children with leukaemia in the Nordic region, and common protocols for ALL treatment have
been in use since 1992. NOPHO has gradually expanded its activities and areas of interest to 
include acute myeloid leukaemia, histiocytosis, pharmacology issues, idiopathic 
thrombocytopenic purpura, myelodysplastic syndrome and HSCT issues. Of the many 
working groups, the NOPHO Events Group focus on severe treatment-related events. As a 
participant in the NOPHO Events Group during the past five years, I have had the opportunity 
to participate in the ongoing surveillance and collection of data on TRDs in the last two ALL 
protocols (ALL-2000 and ALL-2008).  
Personal motivation for the study 
Clinical: As a paediatric oncologist, more than 10 years of daily observations of children with 
side effects from cancer treatment has been a major motivation to undertake this study.  
Network: Being a member of a network with clinicians and researchers such as the NOPHO 
collaboration, with a special focus on toxic events through the NOPHO Events Group, has 
been very inspiring.   
Registry: The ongoing voluntary data collection in NOPHO, originated by clinicians, provides 
the opportunity to approach daily clinical challenges on a large population-based scale with 
data collected in the NOPHO leukaemia registry in Stockholm.  
What this thesis adds 
This thesis adds new knowledge about the incidence, risk factors for and causes of TRDs in 
childhood ALL. The thesis also shows that host genomic SNP risk profiling of patients who 
develop infection during ALL treatment is possible and can identify important metabolic 
pathways related to susceptibility to infection during treatment. The challenges in using 
archival bone marrow samples as the DNA source for multiple biomarker analysis are also 
described. This work shows that clinical research is facilitated by international research 
networks, such as NOPHO, and that such international collaborations are feasible.
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AIMS OF THE STUDY 
x Because toxicity remains a great challenge in the treatment of ALL, one aim of the 
study was to explore the frequency of and risk factors for TRD in two consecutive 
NOPHO ALL protocols, ALL 1992 and ALL 2000. We also tried to compare 
differences in risk of TRD between the two protocols and to identify the causes of
TRDs.
x Infection remains a significant problem in the treatment of childhood ALL, and only a 
few studies have reported on the genetic susceptibility to infection. Another aim was 
to explore the host genomic patterns that may influence susceptibility to infection
during therapy. To achieve this aim, we expanded on our earlier study on the 
mannose-binding lectin gene (MBL) to include 34,000 target SNPs in candidate genes 
of possible relevance for childhood ALL treatment efficacy, immune-inflammatory 
response and toxicity. Using this approach and by exploring the relevant metabolic 
pathways, we hope to identify a genetic risk profile that can predict the risk of 
infection during induction treatment of childhood ALL.   
x Studies on haematological malignancies to date, including those that used bone 
marrow samples as the DNA source have explored only a few biological markers
(Kidas et al., 2009; Lausten-Thomsen et al., 2010; Pabst et al., 1996; Stanulla et al., 
2000; Vince et al., 1998). To our knowledge, no studies have investigated thoroughly 
whether DNA from bone marrow samples is suitable for multiple STR and SNP 
analysis. Therefore, we aimed to evaluate whether archival bone marrow samples are
suitable for multiple biomarker analysis.
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MATERIAL AND METHODS 
Study overview and design 
The study was planned by Bendik Lund, Helge Klungland and Kjeld Schmiegelow, and was 
performed in close collaboration between the SNP/TOX Group (host genomics and toxicity) 
at Bonkolab,Copenhagen, the Center for Biological Sequence Analysis (CBS), Copenhagen, 
and the Genetic Research Group at the Department of Laboratory Medicine, Children’s and 
Women’s Health, Faculty of Medicine, Norwegian University of Science and Technology, 
Trondheim, Norway. In addition, Study I was performed in close collaboration with the 
NOPHO Events Group.  
The three studies used different designs. Study I was retrospective in the sense that
detailed clinical information about the causes of death (TRDs) was collected years after the 
deaths occurred. By contrast, some of the clinical information (anthropometric data, clinical 
and laboratory data, treatment response, events) was collected prospectively during 
monitoring of the respective ALL protocols. Study II was a clinical retrospective case-control 
gene-association study of infectious events. The clinical information used in this study was 
collected retrospectively during an earlier study on MBL-gene polymorphism by our research 
group (Lausen et al., 2006). SNP analysis was performed in 2010 and 2012 after the patients 
had completed their treatment. Study III was an experimental laboratory study of archival 
bone marrow samples that compared biomarkers in bone marrow samples with those in the 
corresponding blood samples.  
Patients and samples 
Patients 
The participants in the present studies were childhood ALL patients aged 1.0 to 17.9 years at 
diagnosis who were treated according to the common Nordic ALL protocols NOPHO ALL-
1992, ALL-2000 and ALL-2008. The ALL-1992 protocol was in use from 1992 to 2000, the 
ALL-2000 protocol from 2000 to 2008, and the ALL-2008 protocol started in 2008 and is still 
running. About 90% of all children with ALL diagnosed within the Nordic region (Iceland, 
Finland, Sweden, Denmark and Norway) are included in the running protocol and have 
agreed to allow the data to be collected and registered in the NOPHO ALL registry at 
Karolinska Institute, Stockholm. As of 31/12/2012, 3,488 childhood ALL patients have been
included in the registry (all three protocols) ("NOPHO Annual Report 2013," 2013). The
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patients were stratified into either a low-risk group (standard or intermediate intensity) or 
high-risk group and were treated according to the protocol that was current at the time. This 
involved chemotherapy treatment for 2-2.5 years in all protocols (Schmiegelow et al., 2010;
Toft et al., 2013). The treatment details are outlined in Papers I and II.    
Papers I and II were based on data from the NOPHO ALL registry. Additional clinical 
data on the causes of death (TRD) were collected through a questionnaire prepared as part of 
the work of the NOPHO Events Group and was collected on behalf of the NOPHO ALL 
Registry (Appendix). As part of another study by our research group (MBL-study) (Lausen et 
al., 2006) additional clinical data were collected retrospectively from the patient files.  
Paper I included patients from the ALL registry between 1992 and 2008 (ALL-1992 
and ALL-2000 protocols) in which 2,735 childhood ALL patients constituted the study 
cohort. Of these, 88 TRDs were identified and served as cases in the study. 
Paper II included patients treated according to the NOPHO ALL-1992 protocol at
Rigshospitalet, Copenhagen, 1992 to 2000. One hundred and thirty-seven patients fulfilled 
these criteria and were included in the previously mentioned study on MBL polymorphisms in 
relation to infection during the first 50 days of antileukaemic therapy (Lausen et al., 2006). 
Blood samples for extended SNP profiling were available for 69 patients, who constituted the 
actual study cohort.  
Paper III included samples from 17 randomly selected Norwegian and Danish patients 
included in the NOPHO ALL-2000 and ALL-2008 protocols.  
Grouping of patients 
In Study II (SNP associations) patients were grouped twice. The first grouping included 
patients who had at least one infectious event (n=48) during the seven-week induction period, 
and the remaining 21 infection-free patients served as controls. The second grouping included 
patients from the first grouping who also had at least one positive blood culture (n=23), and 
the remaining 46 patients served as controls. Culture-positive patients were regarded as 
having a potentially more severe infectious episode.  
Blood samples and archival bone marrow samples 
All blood samples used in the study were obtained during morphological remission and were 
sampled between 1992 and 2010. The archival bone marrow samples were collected from the
archives at Rigshospitalet, Copenhagen, and St. Olavs Hospital, Trondheim. The samples 
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included both Giemsa-stained bone marrow smears and formalin-fixed paraffin-embedded 
(FFPE) bone marrow biopsies. They had been stored at room temperature for 0-10 years. 
Only surplus material was used.  
Candidate genes and SNP selection 
In our gene-association study (Paper II) and evaluation of multiple markers from archival 
samples (Paper III), we chose an extended candidate gene approach. Through an expert panel 
co-ordinated by the SNP/TOX Group at Bonkolab, non-systematic selection of about 2,350
candidate genes with possible relevance for childhood ALL was achieved. The major focus 
for gene selection was treatment efficacy and toxicity, and the following areas/domains were 
included: i) pharmacogenetics, ii) immunogenetics, iii) apoptosis, iv) organ-specific toxicities 
(including thrombosis/bleeding, vincristine neuropathy and pancreatitis), v) cell cycle control 
genes and vi) DNA repair and mitosis. The targeted SNPs within these candidate genes were 
selected based on the influence on their transcript (according to Ensembl (Hubbard et al., 
2002) annotations) as: i) non-synonymous coding, ii) frame-shift coding, iii) regulatory 
region, iv) stop loss, v) stop gain, vi) splice site, vii) within non-coding genes, and viii) within 
mature micro-RNA. This resulted in selection of about 34,000 targeted SNPs. Our research 
group had earlier developed a cost-effective next-generation sequencing capture assay for 
SNP analysis that allows pooling before capture and simultaneous genotyping of several 
samples for a large number of variants (Wesolowska et al., 2011), and this assay was used for
our multiple SNP analysis. 
Whole-genome amplification 
WGA is a method that amplifies small amounts of the DNA template giving a higher DNA 
yield with conserved sequence representation. A new method of WGA called multiple 
displacement amplification has been developed and generates DNA with higher molecular 
weight and better genome coverage (Spits et al., 2006). The method makes use of a DNA 
SRO\PHUDVHĭDQGLVEDVHGRQDQQHDOLQJRIUDQGRPKH[DPHUVIROORZHGE\Vtrand 
displacement, as shown in Fig. 5. 
The same method had been used earlier for amplification of DNA from bone marrow 
smears in our research group (Lausten-Thomsen et al., 2010). To overcome a possible 
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problem with poor DNA yield from our archival samples, WGA was introduced into our 
laboratory work-flow after DNA extraction and before SNP/STR analysis. 
Figure 5. Overview of the principle of multiple displacement amplification (from paper: 
Whole-genome multiple displacement amplification from single cells (Spits et al., 2006)).
1) The random hexamers (represented by a blue line) bind to the denatured DNA (green 
line).
2) 7KHĭ'1$SRO\PHUDVHEOXHFLUFOHH[WHQGVWKHSULPHUVXQWLOLWUHDFKHVQHZO\
synthesized double-stranded DNA (orange line).
3) The enzyme proceeds to displace the strand and continues the polymerization, while 
primers bind to the newly synthesized DNA.
4) Polymerization starts on the new strands, forming a hyper-branched structure.
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Laboratory work 
The laboratory work was performed in Trondheim (LBK/NTNU) and Copenhagen (Bonkolab 
and CBS). Samples were sequenced at commercial sequencing facilities at BGI in Hong Kong 
and at Aros in Århus.  
Preparation of samples 
Blood samples 
DNA from blood was extracted and purified either by standard sodium chloride and ethanol 
precipitation or by using the QIAamp® DNA Mini Kit (Qiagen, GmbH, Hilden, Germany) 
according to the manufacturer’s instructions. 
Archival bone marrow samples 
The bone marrow smears were observed macroscopically and microscopically to visually 
ensure the required minimum cell content. Among the 21 included smears, 12 had cover 
slides, which were separated from their glass slide by immersion in xylene for 2-4 days, after 
which the samples were washed three times with 95% ethanol and air-dried for 2-4 days. PBS 
buffer (0.5 ml) was pipetted onto the glass slide and the cells were carefully scraped off the 
slide surface into a microcentrifuge tube. DNA was extracted using a QIAamp® DNA Micro 
kit (Qiagen) according to the manufacturer’s instructions and stored at – 20 °C. From these 
21 DNA samples, 51 aliquots were taken for further analysis. The REPLI-g® FFPE kit 
(Qiagen) was chosen for WGA because it is designed specifically for fragmented DNA. 
Amplification was performed according to the manufacturer’s instructions. For the bone 
marrow biopsies, a standard microtome technique was used to prepare new sections of FFPE 
tissue with a thickness of 10 ȝP; five sections were prepared per sample. DNA was processed 
by two methods: i) for marker analysis without WGA, DNA was extracted using the 
QIAamp® FFPE tissue Kit (Qiagen) according to the manufacturer’s instructions, and ii) for 
marker analysis including WGA, the REPLI-g® FFPE kit (Qiagen) was used; this kit 
includes DNA extraction, ligation and amplification in the same procedure.  
Quantity and quality measurements  
Because of the expected poor quality and yield of DNA extracted from the archival material, 
quality and quantity assessment was considered a crucial step. To measure DNA
concentration, both spectrophotometry (SP) (NanoDrop® ND 1000 Spectrophotometer, 
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NanoDrop Technologies, Inc., Wilmington, DE, USA) and fluorometry (FM) (Qubit®, 
dsDNA BR assay, Invitrogen, Carlsbad, CA, USA) were used. Gel-electrophoresis was used 
to estimate fragment lengths of both amplified and non-amplified material. 
STR marker analysis
For a subset (n=11) of the patients, STR marker analyses were performed on a total of 31 
archival samples. The AmpFl STR® Profiler® kit (Applied Biosystems, Foster City, CA, 
USA) was used. Amplification was performed according to the manufacturer’s 
recommendation. The 10 STR loci had lengths varying from 107-113 bp (amelogenin, gender
marker) to 281-317 bp (CSF1PO marker). Marker profiles of the archival material were 
compared with the corresponding marker profiles from blood samples. The detection rate of 
STRs was defined as the total number of detected STRs from the particular archival samples 
for all included patients in that group divided by the total number of STRs detected in blood 
samples for the group. This measure takes into account that some patients were either 
homozygous or heterozygous for the respective marker.  
Library preparation
The library was prepared according to the SureSelect Target Enrichment System protocol 
April 2009/November 2010 (Agilent Technologies, Santa Clara, CA, USA) as described 
earlier (Wesolowska et al., 2011). Briefly, 3 ȝJof genomic DNA was sheared in a Covaris S2 
System (Covaris, Inc., Woburn, MA, USA), and the DNA was purified and subjected to end-
repair. For multiplexing, patient-specific barcodes of four bases were ligated to the DNA 
fragments. The library samples were then pooled in groups of 3-8 samples and hybridized to 
custom-designed baits (Sure Select Oligo Capture Library, Agilent Technologies), with two 
baits targeting each SNP (Fig.6). After PCR amplification, the library was sequenced using an
Illumina HiSeq 2000 system (Illumina, Inc., San Diego, CA, USA).  
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Figure 6. Work flow of Agilent’s SureSelect Target Enrichment System. The patient’s DNA 
is fragmented by ultrasound into shorter fragments (Covaris) and hybridized with the 
biotinylated library of RNA capture baits. Hybridized RNA-DNA duplexes are pulled down 
with streptavidin-coated magnetic beads. After washing the beads, the RNA baits are 
digested, and the subset of initial DNA is ready for sequencing. Source: 
www.genomic.agilent.com.
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Outcome measures 
Paper I: Number and percentages of TRDs, causes of TRD, clinical parameters and risk 
factors including WBC, high- and low-risk patients, Down syndrome, CNS-disease and 
HSCT.
Paper II: Number of patients with infectious events and a positive culture; significant SNPs 
and pathways associated with infections; classification and regression tree (CART) analysis 
for predicting infections including SNP profiling and pathway analysis; time-to-an-infectious-
event.
Paper III: DNA concentration measurements; STR detection rate; SNP call rates and 
concordance. 
Ethics 
The study was approved by research ethics committees in Denmark (H-D-2007-0100) and 
Norway (REC-nr 2010/803). Written informed consent was obtained from all patients and/or 
their parents. For the treatment protocols and registration of data in the NOPHO ALL registry 
in Stockholm, informed consent had been collected for all participants. The treatment 
protocols were approved by the national or regional ethics committees in the five Nordic 
countries and the respective national childhood leukaemia groups. The study was conducted 
in accordance with the Declaration of Helsinki.  
Statistics and bioinformatics 
Common statistics
All statistical analyses excluding the bioinformatics were performed by Bendik Lund. In 
Paper I, Stian Lydersen supervised the statistical analysis. The software package SPSS
Statistics (versions 16-20; SPSS, Inc. Chicago, IL, USA and IBM Corp., Armonk, NY, USA) 
was used. Proportions were compared using the chi-square test. Kaplan-Meier plots and 
survival tables were used for time-to-event analysis, and subgroups were compared using the 
log-rank test. In Study I, TRD was used as the main event. Other events (resistant disease, 
relapse or SMN) were censored at the time of these events. Time to TRD was defined as the 
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time from the diagnosis of ALL to the time of death. Patients who experienced no events were 
censored at the time of the last follow-up. Cox proportional-hazard regression analysis was 
performed for multivariate time-to-event analysis. In Paper I, the following covariates were 
includedVH[DJHRU\HDUV:%&RUî9/L), B-cell precursor vs. T-cell 
disease, protocol (ALL-1992 vs. ALL-2000), presence or absence of CNS-disease, Down 
syndrome and HSCT in first complete remission (CR1). For patients who underwent HSCT 
during CR1, a time-dependent covariate was defined as “0” before, and ”1” after the date of 
HSCT; for all other patients, this time-dependent covariate was defined as “0”. In Paper II,
covariates included ANC and age.  
Bioinformatics
All bioinformatic analysis was performed by Agata Wesolowska-Andersen (Papers II and III) 
at CBS/DTU. Briefly, the sequencing reads for each sample were mapped to the reference 
human genome build 37 (GRCh37) using Burrow-Wheelers Alignment algorithms (Li & 
Durbin, 2009; Li et al., 2010). The alignment was refined by means of the alignment score, 
base quality score recalibration and around indel realignment using Genome Analysis Toolkit 
(McKenna et al., 2010), and duplicate sequences were removed with Picard Tools’ (Picard) 
MarkDuplicates function. SNP calling was performed with the SAMtools package (Li, 
Handsaker, et al., 2009) using the default settings. The variants were filtered using the 
vcfutils.pl script from the SAMtools package to remove any bias attributable to base quality 
score, strand or position along the read. The high quality of SNP calling with our multiplexing 
technique has been validated with various PCR methods (Wesolowska et al., 2011). Variant 
annotation was performed with Ensembl Variant Effect Predictor script (McLaren et al., 
2010). The data were converted into .ped and .map file formats readable by PLINK (Purcell et 
al., 2007) using vcftools (Danecek et al., 2011).  
Bioinformatics specifically related to Paper II: The associations between single SNPs and the 
risk of infection and of having a positive culture were analysed by Fisher’s exact test 
implemented in PLINK. Only SNPs with an observed MAF >5% and >50% of non-missing 
genotypes >10× sequencing depth were included in the analysis. A non-strict cut-off of 50% 
of non-missing genotypes was chosen because of the novelty of this genotyping-technique, 
which is often complicated by the presence of genomic regions that are difficult to target with 
capture baits or are difficult to sequence. The obtained p-values were adjusted for multiple 
testing with up to one million adaptive permutations (Besag et al., 1991). Finally, the adjusted 
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p-values were plotted on quantile-quantile plots using publicly available R script 
(http://gettinggeneticsdone.blogspot.com/) and on a Manhattan plot using CIRCOS software 
version 0.52 (Krzywinski et al., 2009). All potentially functional (non-synonymous coding, 
frame-shift coding, stop codon and splice site) SNPs genotyped in this study with MAF > 
0.01 residing in the pathways genes were retrieved for Reactome pathways (Joshi-Tope et al., 
2005) excluding the top two pathway levels. The number of SNPs per pathway ranged from 1 
to 82, and each SNP was encoded by three values between 0 and 1 corresponding to the 
likelihood of each genotype calculated from the VCF file produced by SAMtools (Li, 
Handsaker, et al., 2009). Missing genotype calls were encoded as observed population 
frequencies for the three genotypes. Associations with an infectious event and positive blood 
culture were identified by training artificial neural networks on subsets of SNPs from each 
pathway with threefold cross validation. For each pathway, all combinations of up to three 
SNPs were assessed, and the combinations of SNPs tested were ranked by Matthew’s 
correlation coefficient (MCC) calculated as: 
ܯܥܥ = ܶܲ × ܶܰ െ ܨܲ × ܨܰඥ(ܶܲ + ܨܲ)(ܶܲ + ܨܰ)(ܶܰ + ܨܲ)(ܶܰ + ܨܰ)
where TP is the number of true positives, TN the number of true negatives, FP the number of 
false positives and FN the number of false negatives. For each resulting best combination of 
SNPs for each pathway, the neural network parameters were optimized by testing multiple 
settings of hidden neurons and training cycles. The pathways were then ranked by the MCC 
of the best combination of SNPs for each pathway. For all best combinations, the area under
the receiver-operating characteristic curve (AUC) was calculated with 95% confidence 
intervals with ‘pROC’ R package. CART analyses were performed using rpart R package 
applying threefold cross-validation (Therneau et al., 1997) using the genotypes of the SNPs 
associated with the risk of infection and positive culture with p-values <0.01 together with the 
patients’ age, sex, risk group, immunophenotype and WBC at diagnosis. The same analysis 
was repeated by also including pathway-based predictions achieved from top 10 artificial 
neural network classifiers from the pathway analysis.
Bioinformatics specifically related to Paper III: For the final analysis, SNP call rates were 
calculated, and archival SNP profiles were compared with corresponding blood SNP profiles 
for concordance estimations.  
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RESULTS 
Summary of papers 
Paper I 
Title
Risk factors for treatment related mortality in childhood acute lymphoblastic leukaemia 
Aims of Paper I 
The aim of this paper was to investigate the pattern of TRDs and possible risk factors in the 
NOPHO ALL-1992 and ALL-2000 protocols. Fifty-five TRDs were identified among the 
1,645 ALL-1992 patients and 33 among the 1,090 ALL-2000 patients.  
Main results
Of the total of 2,735 patients, 51 girls and 37 boys (3.2%) with a median age of 4 years (75% 
range 2.0-11.0 years) at diagnosis experienced a TRD. The TRDs comprised 25% of all 354 
deaths in the study population, with 240 deaths after relapse as the largest group. The
incidence of TRDs did not differ between the two protocols (3.4% vs. 3.2%, ALL-1992 and 
ALL-2000, respectively). For the risk groups (stratification based on upfront criteria), the 
cumulative incidence rates of TRD were 1.7 ± 0.4%, 2.4 ± 0.5% and 6.7 ± 0.9% for the 
standard-risk (SR), intermediate-risk (IR) and high-risk (HR) groups, respectively (p < 0.001). 
Five patients died before initiation of anti-leukaemic therapy (0.2%), and the overall 
subsequent risks of induction death and death in CR1 were 1.2% and 1.8%, respectively. 
Infections were the major cause of death and accounted for 72% of all cases, including nine 
deaths from Pseudomonas aeruginosa and 11 deaths from fungal infections. Other causes of 
death included bleeding or thrombosis (eight patients), tumour burden-related toxicity (seven 
patients) and organ toxicity (seven patients). The independent risk factors for TRD were 
identified as female gender (hazard ratio (HR): 2.2, 95% confidence interval (95% CI): 1.4-
3.4), high :%&î109/L) at diagnosis (HR: 3.5, 95% CI: 1.7-7.1), T-cell disease (HR: 
1.9, 95% CI: 1.01-3.7), Down syndrome (HR: 7.3, 95% CI: 3.6-14.9), and HSCT in CR1 
(HR: 8.0, 95% CI: 3.3-19.5).  
40
Paper II 
Title
Host genome variations and risk of infections during induction treatment of childhood 
acute lymphoblastic leukaemia
Aims of Paper II 
The aim of this paper was to investigate the associations between host genomic variations and 
risk of infections during induction treatment of childhood ALL.  
Main results 
Forty-eight (70%) patients experienced at least one infectious event during induction 
treatment, of which 23 patients had at least one positive blood culture. Infectious events and a
positive blood culture were significantly associated with 24 and 21 SNPs, respectively (p <
0.01). CART analysis identified rs11033797 (OR51F1), rs2835265 (CBR1), rs28627172 
(POLDIP3) and rs1129844 (CCL11) as predictive of outcome. Among the 61 patients whose 
readouts were available for all four SNPs, 40 of 41 SNP profile-positive patients experienced 
at least one infectious event compared with five of the remaining 20 patients (HR 9.0, 95% 
CI: 3.4-23.5, which was unchanged after adjustment for neutrophil count). Pathway analysis 
identified variations in “G-protein-coupled receptor (GPCR) downstream signalling”, “Bile
acid and bile salt metabolism” and “Class I MHC mediated antigen processing and
presentation” to be highly predictive of infections. 
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Paper III 
Title
Archival bone marrow samples: suitable for multiple biomarker analysis?
Aims of Paper III
The aim of this paper was to evaluate the usability of archival bone marrow smears and 
biopsies for DNA extraction and purification, WGA, multiple marker analysis including 10 
STRs, and the comprehensive genotyping of 33,683 SNPs with multiplexed targeted next-
generation sequencing. A total of 73 samples from 21 bone marrow smears and 13 bone 
marrow biopsies from 18 Danish and Norwegian patients with childhood ALL were included 
and compared with the corresponding blood samples. 
Main results
We found that the measurement of DNA concentration after DNA extraction was dependent 
on the detection method and that SP overestimated DNA amount compared with FM. The 
mean DNA concentrations were 68.0 ± QJȝ/ and 29.0 ± QJȝL for SP and FM, 
respectively (p < 0.001) foUVPHDUVDQGQJȝ/ DQGQJȝL, respectively,
(p = 0.003) for biopsies. For the STR-marker analysis, all 10 markers were identified in all 
blood samples. The detection rate of markers for smears was 93% compared with 88% for 
biopsies. Analysis of WGA-products in smears and biopsies showed significantly lower 
detection rates of 28% (p < 0.001) and 63% (p < 0.001), respectively. When samples were 
grouped according to time after collection, the detection rate of markers was significantly
higher for samples stored for 0-3 years than for samples stored for 4-10 years. In the STR 
analysis, the detection rate declined slightly for longer fragments. Following WGA, this 
decrease was more pronounced. Of the initial 42 archival samples taken for multiple SNP 
analysis, 13 samples (all derived from smears) had SNP calls >10,000 at 4× read depth. Of 
these, seven archival samples had SNP calls >17,000 (i.e., 50% of about 34,000 intended 
SNPs; Table III, Paper III). Concordance varied from 87% to 100% for total reference SNP 
sites and, except for two samples (ID1 and ID5), 73% to 99% for total variant SNP sites. The 
seven samples belonged to group 1 (n = 2; 0-3 years old, +WGA), group 2 (n = 2; 0-3 years 
old, -WGA) and group 3 (n = 3; 4-10 years old, +WGA). The two smears with highest 
concordance (96-100%) belonged to groups 1 and 2. None of the eight samples derived from 
biopsies had SNP calls >10,000.
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DISCUSSION 
Main findings 
Among the 2,735 patients included in Study I, the overall TRD rate was 3.2%, indicating that 
treatment-related severe toxicity still represents a major challenge in childhood ALL. Because 
the number of patients dying from leukaemia is decreasing, TRDs comprise an increasing 
proportion of overall mortality. We identified tumour burden, infection, bleeding/thrombosis 
and specific organ toxicity as causes of TRD, with infection as the most common cause. To 
reduce toxicity and prevent TRD, more focus is needed to investigate the overall risk factors
for outcome, i.e., the tumour burden, the treatment intensity, and the supportive care. There is 
also the need for increased knowledge about the relevant host genetic factors. Multiple 
regression analysis identified female gender, high WBC at diagnosis (> 200 × 109/L), T-cell 
disease, Down syndrome and HSCT in CR1 as risk factors for TRD.   
In our study on host genetic risk factors for infectious events during induction 
treatment, we identified a SNP risk profile that could predict the risk of an infectious event 
with 98% accuracy among SNP profile-positive patients. In addition, metabolic pathways 
related to the risk of infectious events were identified suggesting the possible underlying 
mechanisms involved in the development of infections among ALL patients. We also 
demonstrated a potential model for further research in this area and found that genetic risk 
profiling may be possible even in studies with a relatively small sample size. 
When investigating the use of archival material for multiple marker studies, we found 
that archival bone marrow smears and biopsies can be used for DNA extraction and 
purification. The importance of the method used to measure DNA concentration measure 
method was illustrated by our findings that SP overestimated DNA concentration compared 
with FM. Multiple STR analysis was successful for both smears and biopsies, but older 
samples had a lower success rate compared with younger samples. We also found that 
multiple SNP array analysis from archival samples may be possible, but this method was 
successful for only a few samples. Hence, the method must be optimized. 
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Main findings in relation to other research 
TRD: treatment intensity vs. toxicity 
Our finding of an overall TRD rate of 3.2% is similar to that found in other studies (Blanco et 
al., 2012; Prucker et al., 2009). The TRD rate did not change significantly between the ALL-
1992 protocol and the ALL-2000 protocol. This fits well with a review by Blanco and co-
workers showing that the TRD rate has not changed much over the past 30 years (Blanco et 
al., 2012).  
Successful treatment of childhood cancer implies a fine balance between treatment 
intensity and side effects. In our study, TRDs accounted for 25% of the 354 deaths in the 
study population. Most of the other deaths occurred after relapse. The percentage of deaths 
caused by relapse or treatment-related toxicity might be age-dependent as shown by Pichler et 
al. (Pichler et al., 2013). They found that the inferior overall prognosis in adolescents was 
caused by a higher TRD-rate and not by relapse, indicating either that adolescents more often 
receive intensive treatment or that adolescents are less able to tolerate treatment compared 
with younger children. We found that age (10.0-14.9 vs. 1.0-9.9 years) was not a risk factor 
for TRD, but we did not compare between deaths after relapse and TRD.   
Having a relapse indicates more chemotherapy-resistant disease and significantly 
decreases the chance of a cure (Bhojwani et al., 2013; Nguyen et al., 2008). High treatment 
intensity reduces the chance of a relapse, but increases the risk of severe side effects, and vice 
versa, as illustrated in Fig. 7.  
Figure 7.
B)
A)   Treatment intensity 
 Risk of death from disease
 Risk of death from treatment (=TRD)
 Treatment intensity 
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 Risk of death from treatment (=TRD)
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This concept is consistent with our observation (Paper I) that the cumulative incidence 
of TRD was higher in those who received more intensive treatment: 1.7%, 2.4% and 6.7% for 
the SR, IR and HR groups, respectively.
A great challenge for clinicians is to use treatment at an intensity that is required for 
disease control and to avoid relapse while at the same time not overtreating patients and 
causing intolerable side effects. The question is: how to allocate the individual patients to the 
most appropriate treatment? At diagnosis and after response evaluation, the following is only 
partly known: i) which patients will respond to the chemotherapy prescribed in terms of 
disease control (blast cell chemotherapy sensitivity, relapse risk), and ii) which patients have 
host genetic factors that make them more vulnerable to side effects. As outlined in Paper I, 
risk-adapted therapy is based on different parameters related to the disease, such as the WBC 
at diagnosis, immunophenotype (T- or B-cell), CNS/testicular involvement, cytogenetic 
alterations, and the  response to the initial therapy. However, some patients experience TRD 
even when having low-intensity treatment (SR and IR groups). Hence, for these patients, the 
prescribed low-intensity drug-combinations are in fact too intensive. An example of 
incorporating the host pharmacogenetics into drug dosing is the use of TPMT SNP-
genotyping for 6-MP dosing. This was not part of the ALL-1992 protocol, but was 
incorporated in the ALL-2000 protocol and has been continued in our ongoing ALL-2008 
protocol. This approach is also consistent with modern pharmacological thinking about 
personalised medicine. The paradigm of “all patients same drug and dose” seems not 
appropriate in terms of the increasing knowledge about host genetics and disease biology 
(Blay et al., 2012; Davidsen et al., 2008; Hudson, 2013) .   
TRDs occurred at different phases of therapy. Seven patients died from tumour 
burden-related problems within the first days after the diagnosis, including five patients who 
died before the start of any anti-leukaemic treatment. Handling of such patients is challenging 
and the outcome is clearly related to the rapidity of the diagnostic work-up and initiation of 
therapy. Modern treatment with recombinant urate oxidase (rasburicase) has been shown to be 
effective for prophylaxis and treatment of urate-related problems of tumour lysis syndrome in 
childhood malignancies (Pui et al., 2001). This makes it possible to initiate anti-leukaemic 
treatment rapidly with full dose GC therapy after administration of rasburicase. This approach 
might have prevented the tumour burden-related TRDs seen in this study. One can argue 
whether these patients should be classified as TRDs. If “treatment” means “chemotherapy” or 
“GC-treatment” these cases might instead be classified as “disease-related death”. However, 
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these patients are challenging for the treating physician and highlight the clinical spectrum of 
severely ill ALL patients. Exploring such patients and their causes of death focuses attention
to better handling the first days after the diagnosis.  
Treatment-induced immunosuppression 
Treatment-induced immunosuppression includes neutropenia, impaired humoral antibody 
response, impaired cell-mediated immunity, phagocytic defects and disturbed cytokine 
functions (Eyrich et al., 2009; Hann et al., 1997; Pui, 2006). All of these factors contribute to 
the increased risk of infection. Our findings that 70% of patients experienced at least one 
infectious event during induction treatment and that the first event happened relatively early 
after the start of treatment (median time to infection, 2.5 days; Paper II) are consistent with 
the relationship between these factors and the risk of infection. Chemotherapy-related risk of 
infections has been well documented by others (Afzal et al., 2009; Graubner et al., 2008;
Stabell et al., 2008). In our study, infections were the most common cause of TRD (PaperI), a 
finding that has also been reported by others (Conter et al., 2000; Hargrave et al., 2001;
Prucker et al., 2009; Wheeler et al., 1996). Hence, there is a widespread use of antibiotics 
both in infectious events (with or without neutropenia) and as prophylaxis. In cases of febrile 
neutropenia or any suspected infectious event, empirical therapy is based on the most 
probable causative organisms and their likely susceptibility patterns. Different antibiotic 
regimens are effective, many of which include either a combination of penicillin and an 
aminoglycoside or, as monotherapy, a broad-VSHFWUXPȕ-lactam such as a carbapenem 
(Stabell et al., 2008; Yildirim et al., 2008).  
Prophylactic antibiotics are used to varying degrees against bacteria. A review by van 
de Wetering et al. (van de Wetering et al., 2005) showed that oral prophylactic antibiotics
decreased G-negative bacteraemia and infection-related mortality in oncology patients during
neutropenic episodes. However, only three of the 22 trials reviewed included paediatric 
patients. Larger prospective studies are needed to explore whether antibacterial prophylaxis 
during the neutropenic phases in the first three months of anti-leukaemic therapy can reduce 
the risk of infectious TRDs in patients with childhood ALL.  
A well-known and potentially fatal infection in immunocompromised patients is
Pneumocystis jirovecii pneumonia (PCP). Trimethoprim-sulfamethoxazole (TMP/SMX) has 
been shown to be an effective prophylactic against PCP (Green et al., 2007), but there is no 
international consensus regarding the dosing of TMP/SMX prophylaxis used in childhood 
malignancies. Giving the drug three days a week seems as effective as giving it daily, as 
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shown in a study by our research group (Levinsen et al., 2012). In our present study (Paper I),
only one patient died from PCP. There was no uniform approach to prophylaxis against PCP
infection during the study period, and no patient-specific data on prophylaxis against PCP 
were available. Thus, it is unknown to what extent local strategies for PCP-prophylaxis may 
have contributed to the low frequency of mortality from PCP in our study.  
The finding that 76% of the TRDs occurred in the first 80 days after the start of 
treatment, including nine of the 11 deaths due to fungal infection, shows that this treatment 
period is the most crucial with regard to the risk of severe infection and immunosuppression, 
mainly caused by the initial tumour load and very intensive chemotherapy treatment including
GCs. The fact that 52 % of the patients who experienced TRD because of infection were not
neutropenic during the week preceding death shows that the risk of severe infection not only 
is associated with neutropenia, but also with suppression of other parts of the immune system.  
Some infectious deaths occurred despite adequate antibiotic treatment according to the 
resistance pattern of the microorganism(s) in question. This raises the question of a possible 
role of critical host genetic factors including pharmacogenetics (Davidsen et al., 2008;
Karathanasis et al., 2009) and immunogenetics. Studies on genetic polymorphisms in 
immunoregulating mediators have shown an association with outcome during childhood 
leukaemia induction therapy (Kidas et al., 2009), in childhood AML patients (Lehrnbecher et 
al., 2005), in childhood malignancies in general (Neth et al., 2001) and in post-HSCT patients 
(Middleton et al., 2002; Shamim et al., 2006). However, most studies are candidate gene-
based involving only a few genes, and genome-wide studies of variations within the immune 
response involving multiple genes and haplotypes are lacking. Identification of possible 
immunogenetic risk profiles at the start of therapy might be helpful in the development of 
risk-adapted and individualized supportive care.  
Of the 88 TRDs, 15 (17%) were caused by specific organ toxicities or haemostasis-
related causes. Most organ-specific or haemostasis-related toxicities, such as pancreatitis, 
liver-toxicities and thrombosis or bleeding, are treated successfully by careful supportive care;
therefore, general conclusions about these small subgroups cannot be drawn. Infections seem 
to be the most critical issue relating to TRD and exploring host genomics seems reasonable, 
as others have indicated (Graubner et al., 2008). 
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SNP risk profiling 
To some extent, it remains unknown why some patients develop severe infections during 
treatment while others, even those within the same sex, age and risk group, experience only 
mild infections. We were therefore interested in exploring the possible role of inherited 
genetic factors. First, we focused on identifying a SNP profile predictive of infectious events 
regardless of its biological relevance. Second, we focused on genes and pathways of relevance 
for infections in children with ALL to increase our understanding of the underlying biological 
mechanisms.
Our findings that 24 and 21 SNPs were associated with infectious events and positive 
blood cultures, respectively, (Fig. 8, from Paper II), strongly suggest that common host 
genomic variants within immune function, drug disposition and other intracellular signalling 
mechanisms play a critical role in the risk of susceptibility to infection in children with ALL.  
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Figure 8. (Paper II). Manhattan plot showing the association of SNPs with infectious events 
(inner ring of blocks) and positive culture (outer ring of blocks). The radius represents the –
log10 of p-values, and each SNP is plotted based on its position in the chromosome and as a
function of its p-value. Red dots represent SNPs with p-values <0.01. Grey dots represent 
SNPs with p-values >0.01. Blue tick marks represent the positions of baits used for target 
capture. 
Using CART analysis, we identified a four-SNP risk profile based on our primary 
findings of 24 SNPs associated with the presence of an infectious event. For patients termed 
“SNP profile positive”, 40 of 41 patients experienced an infectious event compared with only 
five of the 20 “SNP profile-negative” patients. To our knowledge, multiple SNP-profiling has 
not been used to predict the risk of infection in childhood ALL patients. SNP data and CART 
analysis has been used in only a few studies of childhood ALL, but with other end-points such 
as ALL susceptibility and risk of osteonecrosis (Chan et al., 2011; Kawedia et al., 2011).
CART analysis is a mathematical tool helpful for identifying the most predictive SNPs related 
to outcome. The SNPs included in the profile do not necessarily belong to the same pathways,
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but are mathematically selected as the most predictive ones. The significant SNPs might also 
not be causative in pathways related to infections, but may serve as markers (tag-SNP) 
because of linkage disequilibrium with other causative SNPs. The simplicity of CART-
analysis makes the risk profile data more comprehensible and clinically applicable than 
complex pathway interactions.  
Figure 9. CART (classification and regression tree) diagram for “infectious event” showing 
the most predictive SNP-sequences and the corresponding genes (Paper II).
The four predictive SNPs in our CART analysis (Fig. 9, from Paper II) link four genes 
to the risk of having an infectious event and two genes to the risk of a positive culture. The 
SNPs and genes, and their relationships with ALL, are summarized in Table II. To our 
knowledge, the olfactory receptor OR51F1-gene has not been related to infections, childhood 
leukaemia or chemotherapy side effects. It was included in our multiple SNP analysis 
platform because it resided in an intron of another gene, MMP26, which was selected because 
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of its relationship with tumour invasion and metastasis. Some theoretically functional analogy 
between germinal centre B-lymphocytes and olfactory sensory neurons might exist (Otaki et 
al., 2005), but one can only speculate whether there is a hitherto undetected link between 
OR51F1 and the risk of infection. It might also be a false-positive finding reflecting 
mutational heterogeneity frequently seen, particularly for olfactory receptors (Lawrence et al., 
2013). The CBR1-gene is associated with metabolism of anthracycline (Bains et al., 2009), 
which is part of the induction treatment. Patients with reduced metabolism of doxorubicin 
might experience increased toxicity, causing prolonged neutropenia and thereby an increased 
risk of infection. An association with infection in immunocompromised patients has not been 
reported for the POLDIP3-gene, but it has been associated with sleep patterns in childhood 
ALL patients during dexamethasone treatment (Vallance et al., 2010). The CCL11-gene 
relates to asthma, allergic diseases and parasite infections (Simons et al., 2005), but as an 
inflammatory signalling molecule, it might play a role in host defence against infection in 
childhood ALL patients.
For the other end-point in our study, culture-positive patients, the most predictive SNP 
was located in the FLNB-gene, which encodes filamin B, a cytoplasmic protein that binds 
actin and connects plasma membrane to the intracellular cytoskeleton, thereby changing the 
cell shape. It is expressed in vessels and endothelial cells, and participates in the process of 
angiogenesis (Del Valle-Perez et al., 2010). Filamin B resembles filamin A (both are actin-
binding proteins participating in communication between the cell membrane and the 
cytoskeletal network) which is associated with increased vascular permeability (Griffiths et 
al., 2011) and increases the risk of severe sepsis. Whether this also applies to filamin B is 
unclear. 
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Metabolic pathways related to infections during ALL treatment 
Infections are considered complex diseases involving the interplay between many genes as 
well as host interactions with the environment. Exploring the pathways of infection seems to 
be more biologically relevant than performing single-gene/SNP studies. We were interested in
identifying the crucial pathways involved in infections during induction therapy; this 
approach was possible because our starting point was the genes and SNPs with known 
biological functions.
We identified two pathways that were most predictive of an infectious event: “GPCR 
downstream signalling” and “Bile acid and salt metabolism”. In addition to be the target of 
many drugs, many GPCRs are expressed on the cell surface of many cells, including 
neutrophils, were they participate in host defence and inflammation (Fig. 10) (Futosi et al., 
2013).
Figure 10. G-protein-coupled receptor signalling in neutrophils. G-protein-coupled receptors 
in neutrophils signal SULPDULO\WKURXJKWKH*ȕȖKHWHURGLPHUDFWLYDWLQJWZRSDUDOOHOSDWKZD\V
WKURXJK3/&ȕ(phospholipase &ȕ) DQG3,.Ȗ (phosphatidylinositol .Ȗ). The 
activation of Src-family kinases likely proceeds through (an) independent and yet 
incompletely understood pathway(s) (question marks). Source: Futosi 2013 (Futosi et al., 
2013).
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There is increasing evidence that rapid effects of GCs (as opposed to delayed GC 
effects mediated by intracellular GC-receptors) signal via GPCRs (reviewed by Tasker et al.) 
(Tasker et al., 2006). One can speculate whether linkage of the “GPCR downstream 
signalling” pathway to infectious events in our study occurs via GPCRs in neutrophils or via 
GCs or both. A connection with GCs fits well because GCs are used widely during induction 
therapy in most childhood ALL treatment regimens including our Nordic protocols (treatment 
outlined in Paper I). Concerning the pathway “Bile acid and salt metabolism”, some of the 
genes involved are also involved in GC-metabolism (SLCO1B-family and CYP27A1;
Supplementary Table 4, Paper II); hence, GC-metabolism might be the common denominator. 
Whether these pathways also relate to deaths caused by infection is unknown but, 
interestingly, many of these deaths (including those caused by fungi) occurred during the first 
months of treatment, which overlapped with the timing of GC treatment. Again, this 
illustrates the immunosuppression occurring during the first part of treatment. GCs have 
profound effects on immune function in patients treated for inflammatory or rheumatic 
diseases and in childhood ALL patients (Marino et al., 2009; McDonough et al., 2008). 
Linking pathways relevant to infection and GC metabolism seems reasonable. 
In relation to the other end-point, “culture positive”, the “Interferon-signalling 
pathway” was the most significant pathway identified. Multiple biological functions are 
mediated by interferon signal transduction; e.g., anti-tumour effects, anti-viral effects, cell-
cycle arrest, anti-angiogenic effects, apoptosis, cell-differentiation, immunomodulation and 
protein synthesis (Uddin et al., 2004). It is unclear which of these effects are relevant to 
immunosuppressed children with ALL, but our findings might help generating hypothesis and
ideas for future research.  
Archival samples 
DNA extracted from archival samples, such as biopsies and smears, has great potential in
genetic studies. We have evaluated the suitability of DNA extracted from archival bone 
marrow samples for application in multiple STR and SNP analysis. We observed significant 
differences between DNA concentration measured using SP and FM, and found that SP
overestimated DNA concentration compared with FM. Others have also found higher 
concentrations of nucleotides derived from FFPE-samples measured by SP compared with 
FM (Deben et al., 2013). Overestimation of DNA concentration by SP analysis might be 
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caused by contamination with other molecules including RNA or free nucleic acids (Holden 
et al., 2009). Haque et al. (Haque et al., 2003) compared the DNA concentrations measured 
by SP with two FM methods and found that SP was the most concordant and precise DNA 
quantification method. Correct estimation of DNA concentration is crucial. One consequence 
of concentration overestimation is that the true DNA amount is less than that estimated, and 
there may be an insufficient starting amount of DNA for downstream analysis, which may 
lead to failure or bias in subsequent analyses. The most reliable DNA estimation tool in our 
studies seems unclear, but overestimation of DNA concentration was regarded as most 
hazardous; hence, the concentrations based on FM were used in our STR and SNP analysis.  
Because the DNA yield varied substantially between individual archival samples and,
for some samples, was very low (500 ng), we used WGA in an attempt to increase the DNA 
yield, especially for further downstream multiple marker analysis. We found apparently high 
yields of DNA after WGA when measured by SP and FM, and long fragment-lengths on gel-
electrophoresis. However, WGA-samples were less effective in multiple marker analysis, 
especially in SNP analysis. For STR markers, we found that fragments up to 250 bp in length 
could be amplified and that amplification success decreased with increasing fragment length, 
especially for the WGA-products. Others have also had difficulties with amplification of 
DNA fragments >200-300 bp from FFPE samples (Talaulikar et al., 2008; Vince et al., 1998). 
The efficiency of WGA depends partly on DNA fragment length, and it is recommended that
DNA substrates should include some fragments with lengths of at least 500 bp. This might 
explain, at least partly, the reduced quality of the WGA samples.  
Earlier reports that included bone marrow smears from leukaemia patients focused on 
single markers often related to genetic aberrations in the malignant clone and, to a lesser 
extent, host genetics. Our findings of high detection rates in STR marker analysis based on 
non-WGA samples suggest that archival material might be suitable for DNA extraction and
marker analysis for the study of host genetics.  
We found that the detection rate was higher in the samples that had been stored for a 
shorter time compared with older samples. This suggests that the quality of DNA declines 
during longer storage periods, which is consistent with other studies (Cronin et al., 2004). 
However, some authors have discussed whether this relates more to the conditions of 
preservation, such as temperature, humidity and pH (Okello et al., 2010), whereas others have 
also shown that long-term storage of FFPE tissues or bone marrow slides has no significant 
negative effect on downstream applications (Anderegg et al., 1998; Ludyga et al., 2012). 
There are many possible explanations for these contradictory findings including differences in 
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methods for embedding, nucleic acid extraction and marker detection (Okello et al., 2010). To 
identify the factors most important for our material required further detailed investigations
beyond the scope of this study.
Regarding multiple SNP sequencing, only a few samples could be analysed 
completely, and no general conclusions can be drawn. SNP profiling with multiplexed 
targeted sequencing is a complex laboratory procedure, and errors can be generated at many 
steps, not least because of poor-quality DNA extracted from archival samples. Interestingly, 
however, we succeeded with some samples, suggesting that multiple SNP profiling based on 
DNA from archival bone marrow smears might be feasible with some adjustments of the 
laboratory set-up. We also managed to perform SNP profiling successfully using two samples 
without WGA, suggesting that WGA might not be necessary but may introduce bias or noise 
into the analysis. However, we succeeded with five WGA samples, and we have no definitive 
data on which to recommend WGA. Without WGA, there might be an insufficient amount of 
DNA amount from one smear. A solution might be to use two or three smears per sample to 
increase the DNA yield from each patient, or to use other microarray-based methods, without 
target selection and multiplexing, that require a smaller starting amount of DNA.  
Strengths and limitations 
Strengths: In Paper I, data from a health registry (Nordic ALL registry in Stockholm) were
used, which makes the study population-based; hence, the data on the incidence and
prevalence are highly reliable, and the risk of selection bias was low. A multiple gene/SNP 
approach was used in which the biological functions of the genes/SNPs involved are known,
making it easier to interpret the results within a biological context and making pathway 
analysis possible. We also demonstrated that multiple gene-association studies are possible 
even in small cohorts and that our results can be applied to the clinical setting. Our study 
design can also be applied to many other clinical end-points; for instance, to study other 
toxicities such as toxic death, pancreatitis, thrombosis and osteonecrosis.  
Limitations: TRDs were grouped into five different groups. Grouping the causes of TRDs is
problematic because there is no clear internationally accepted grouping or even a definition of 
TRD. Similarly, the “phenotype” used as the end-point in our SNP/gene-association study, 
namely “infectious event”, is heterogeneous and not defined precisely, which might have
contributed to bias in the associations identified. Our finding of a SNP risk profile has not 
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been validated in an independent patient cohort; this should be done before these findings are 
applied in the clinical setting.
Investigations of a set of candidate polymorphisms a priori exclude identification of 
other important but unknown biological mechanisms. The sample size of our cohort was 
small. The same findings in a larger cohort would have been more valid. DNA was available 
for only about 50% of patients in the original cohort, which might have contributed to 
selection bias. 
Clinical implications 
These studies highlight the importance of focusing on infections and supportive care during 
ALL treatment. If our SNPs/pathways are confirmed as predictive in independent cohorts or if
similar SNPs/pathways are identified as risk factors for infectious TRDs, genetic risk 
profiling at the start of treatment may be useful for early identification of patients at risk.
In our SNP-profiling study, 41 out of 61 patients were SNP-profile positive. Of these, 
40 had an event. Of the profile negative patients, 5 had an event. An intervention in the 41 
profile positive patients would have given the following:  i) unnecessary intervention in 1 
patient, ii) lack of intervention in 5 of the event-patients with negative SNP profile, and iii) 
correctly intervention in 40 of 45 (89%) event-patients (Fig. 10). Subtracting the number of 
patients with unnecessary intervention and lack of intervention, optimized treatment would
have been offered for 55 of the total of 61 (90%) patients. Such intervention may include: i) 
reduced or modified anti-leukaemic treatment intensity, ii) prophylactic antibiotic therapy, iii) 
immunological reconstitution (e.g., immunoglobulin substitution) and iv) granulocyte colony-
stimulating factor therapy.  Concerning reduced treatment intensity, this may only be 
considered for patients at risk of infectious death, and has to be balanced against a potential 
increase in relapse-risk. 
Figure 11.
n=1
n=5
n=40 Profile+ patients
Infectious events 
patients
Total: 61
n=15
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The study on archival samples might not be transferred directly into the clinical 
setting, but is relevant for retrospective studies including study subjects who have died 
(TRDs). In other studies, DNA sampling can be simplified by use of archival material instead 
of obtaining new DNA samples (e.g., from new blood samples).  
Suggestions for further research 
Risk factors and causes of TRDs and other severe events are and should be a continuous focus 
for all cancer treatment collaborative groups. A better system to classify TRDs or childhood 
cancer deaths in general should be developed so that different treatment regimens can be 
compared more easily with regard to toxicity and survival. Our SNP risk profile including 
infectious TRD as the end-point, requires validation in a larger independent cohort (planned 
as part of our next NOPHO ALL-2014 protocol). If our findings are replicated, further 
biological studies including those on gene-expression and biological signalling may identify 
the mechanisms underlying the development of infectious events during treatment by, for 
example, dissecting causal genotype-phenotype relationships.  
Concerning archival bone marrow samples, a more robust SNP sequencing laboratory 
model should be developed to include a more simplified model with fewer analysis steps in 
the laboratory work-flow.    
During our studies on TRDs and surveillance of the ongoing NOPHO ALL-2008 
protocol, we recognized high TRD rates among high-risk adolescent patients that seemed to 
be related to body mass index (BMI, kg/m2). Significantly lower EFS rates among obese 
patients have also been reported by others (Butturini et al., 2007). Our observation initiated a 
new study aiming to evaluate possible relationships between BMI or BMI-changes throughout 
treatment and the TRD-rate in NOPHO ALL-2008 protocol patients. Preliminary results have 
shown a borderline significantly higher mean BMI standard deviation score among the 
patients who died of TRD compared with the other patients. This finding was more 
pronounced in the high-risk group (results presented in a poster at the NOPHO Annual 
Meeting in Uppsala, 2012). This case-control study is ongoing and will include height and 
weight data at the time of the event (TRD) to see whether changes in BMI during treatment
are related to the risk of TRD. 
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CONCLUSIONS 
In this study, we have shown that infections remain a major challenge in the treatment of 
childhood ALL and that infectious TRD is one of the most severe side effects of treatment. 
Accordingly, studies addressing the prevention of TRD have become as important as efforts 
to overcome the resistance to the anti-leukaemic therapy. Through our identification of a 
SNP-risk profile, we have shown that host genomic variation seems to play an important role 
in the risk of having an infectious event during treatment. Such genetic risk profiling can 
identify patients at risk of severe events at the start of treatment, and more risk-adapted 
therapy can be given with the intention of reducing severe side effects and increasing OS. 
Most genetic studies rely on the use of DNA from biobanks or DNA extracted from 
freshly obtained samples. This presents a complication if the patient has died. We have shown 
that archival bone marrow samples from leukaemia patients are suitable for DNA extraction 
and multiple marker analysis. Although increasing the total amount of DNA, WGA reduces 
the analysis quality. DNA quality depends on the sample storage time, and STR-marker
analysis based on archival samples of relatively short storage time (0-3 years) without WGA 
produces the best results. Complex SNP analysis that includes thousands of polymorphisms in 
a single analysis might be feasible, but the method must be optimized.    
Notes 
Preliminary results of this study have been presented as follows:
1) Oral presentation at NOPHO Annual Meeting in Aarhus, 2009 
2) Oral presentation at NOPHO and NOBOS Annual Meeting in Tromsø, 2010 
3) Poster presentation at NOPHO Annual Meeting in Uppsala, 2012 
4) Poster presentation at the 54th ASH (American Society of Hematology) Annual 
Meeting, Atlanta, 2012  
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TREATMENT RELATED DEATHS IN NOPHO ALL-2000
Patient Identification Number: 
(Set by study coordinator =NOPHOnr)
1. Date of birth: __________(ddmmyyyy)    Gender: Female ͕
Male ͕
Immunoglobulines at diagnosis:
a. a.IgA   _________       
b. b.IgM  _________ 
c. c.IgG   _________ 
Units in: micromol/l ͕  gram/l ͕
Viral immune status before treatment (set “x”):
Specific IgG PCR
pos neg not done pos Neg not done
CMV
EBV
HBV
HCV
HIV
Parvovirus B19
HSV
Morbilli
VZV
ALL therapy overall:
a. 'HDWKEHIRUHDQ\DQWLOHXNHPLFWKHUDS\<HV͕1R͕
Clinical features before 
start of treatment: Yes No Unknown If “yes” duration  from start of symptom to start of treatment:
Fever (>37,5qC ax)
Infection
Respiratory tract symptoms
Bleeding
Petechiae
Skin rash
Fatigue
Headache
Limb/joint pain
Other symptoms (specify):
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b. Date of start: ___________   Treatment protocol: _______________________ 
c. Major changes from protocol treatment: 
i. Yes ͕    No  ͕
    If so, specify: _____________________________________________ 
_______________________________________
d. BMT:    
<HV͕  No͕
1. Conditioning regimen: ________________________________ 
2. Conditioning start date: ___________  
3. Transplantation date: ___________ 
Recent ALL– therapy:  
Specify all chemotherapy given during the last 3 weeks before death (or send copy of 
chemotherapy forms)
Drug Total dose pr m²
Date begin
(ddmmyyyy)
Date end
(ddmmyyyy)
Clinical features and physical examination at start of the last course of 
chemotherapy before death: 
Start date: ______________ 
Blood samples at start:  White bloodcell count: ______ x109/L ; Neutrophil count: ______x109/L;  
      Lymphocyte count: _______x109/L; Thrombocyte count:________x109/L;
Hemoglobin: ________ g/L; mmol/L
Yes No Unknown
Fever (>37,5qC ax)
Infection Local ͕ Systemic  ͕
Respiratory distress
Bleeding If yes, site:
Skin rash If yes, site: 
Splenomegaly Cm below costal margin:
Hepatomegaly Cm below costal margin:
Lymphadenopathy
FP
If yes, site:
CNS symptoms/signs If yes, specify: 
Other symptoms 
(specify):
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2. Complications the last 3 weeks preceding death:
   Yes No   Unknown    Organism(s): 
Pneumonia   ͕    ͕ ͕        _________________________________ 
Bact. sepsis   ͕  ͕ ͕        _________________________________ 
Septic shock    ͕  ͕ ͕        _________________________________
Meningitis   ͕  ͕ ͕     _________________________________
Viral infection  ͕    ͕ ͕         _________________________________ 
      Site:______________________________ 
Fungal inf.       ͕    ͕ ͕         _________________________________ 
      Site:______________________________ 
Artificial ventil.  ͕    ͕ ͕ Start date: _________ End date:________ 
Surgery   ͕    ͕ ͕ Which: ___________________________ 
Date:______________ 
Bleeding   ͕  ͕ ͕
Encephalopathy  ͕  ͕ ͕
Hepatic toxicity/failure (ULN=Upper Limit Normal; LLN=Lower Limit Normal): 
* ALAT: Normal    ͕           >ULN-2,5 x ULN ͕   
>2,5-[8/1͕           >5,0 x ULN ͕          
* Bilirubin: Normal    ͕!ULN-1,5 x ULN  ͕    
>1,5-[8/1͕            >3,0 x ULN ͕          
* Albumin: Normal    ͕     <LLN-3,0 g/dL ͕   
-3,0 g/dL    ͕ <2,0 g/dL   ͕    
  * Other signs of liver failure:
    ____________________________________________ 
Renal toxicity/failure : 
* Creatinin: Normal    ͕8/1-1,5 x ULN ͕   
>1,5-[8/1͕           >3,0 x ULN ͕
 * Requiring  GLDO\VLV"<HV͕ 1R͕    
* Other signs of renal desease/failure:
   _____________________________________________ 
Cardiac failure:
* Left ventricular function: 
o Normal      ͕
o Fraction of shortening (FS) - <30% ͕
o FS <24%        ͕
o Congestive Heart failure     ͕
Other, specify: _______________________________________________
___________________________________________________________
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Clinical features and physical examination at the time of death:
Yes No Unknown
Fever (>37,5qC ax)
Infection Local ͕ Systemic ͕
If local, site: 
Respiratory distress
Bleeding If yes, site:
Skin rash If yes, site: 
Splenomegaly Cm below costal margin:
Hepatomegaly Cm below costal margin:
Lymphadenopathy
FP
If yes, site:
CNS symptoms/signs If yes, specify: 
Other symptoms 
(specify):
Artificial implants present during the last 3 weeks before death:
a. IV access:  Port-a-cath   ͕ No implants ͕
Hickman-catheter ͕
Other(specify): _______________________________ 
b. Other artificial implants: ___________________________________ 
Date of death: _____________
* Set a mark in the protocol for the time of death: 
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Hematological data before death:
Last bone marrow examination before death: Date: ________________ 
Percentage of blasts: M0 ͕ M1 ͕ M2 ͕ M3 ͕
Max CRP during ongoing infection: _________ Date: ____________________ 
Microbiological analysis during the last 3 weeks before death:
Date Material Test (culture, PCR, etc) Organism 
Antibiotics during the last 3 weeks before death : 
(All kinds included, even PCP prophylaxis) 
Start 
date
Stop 
date Antibiotics
Reason for change (set “x”):
Specific 
organism 
/resistance 
pattern
Resistant 
bacteria
Lack of 
clinical 
response
Date
Days before death -6 -5 -4 -3 -2 -1 0
WBC (x109/L):
ANC (x109/L):
Hemoglobin (g/L;mmol/L):
Thrombocyte count (x109/L):
Lymphocyte count (x109/L):
CRP
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Cause of death:
 a) Autopsy performed:  Yes͕ 1R͕
b) Main cause of death: 
Tumor lysis compl.  ͕  Interstitial pneumonitits ͕
  Leukostasis   ͕  ARDS    ͕
  Thrombosis   ͕  Cardiac toxicity  ͕
Bleeding   ͕  Encephalopathy  ͕
Renal failure   ͕  Multi organ failure  ͕
VOD    ͕  Unknown   ͕
  Infection:
   Viral   ͕2UJDQLVPBBBBBBBBBBBBBBBBBBBBBBBB
Site:__________________________ 
   Bacterial  ͕2UJDQLVPBBBBBBBBBBBBBBBBBBBBBBBB
       Site:__________________________ 
   Fungal   ͕2UJDQLVPBBBBBBBBBBBBBBBBBBBBBBBBB
       Site: __________________________ 
   Parasitic  ͕2UJDQLVPBBBBBBBBBBBBBBBBBBBBBBBBB
       Site: __________________________ 
   Unknown  ͕
  Other, specify:    ______________________________ 
 c) Contributing causes of death: ________________________________________ 
      ________________________________________________________________ 
Further comments:
____________________________________________________
____________________________________________________
____________________________________________________
____________________________________________________
____________________________________________________
____________________________________________________
Trondheim, Norway, January,  2008  
On behalf of the NOPHO ALL-event group, 
Bendik Lund, MD (study coordinator)  Ann Elisabeth Åsberg, MD   
Kjeld Schmiegelow, Professor Dr. Med.
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Risk Factors for Treatment Related Mortality in Childhood Acute Lymphoblastic
Leukaemia
Bendik Lund, MD,1,2,* Ann A˚sberg, MD, PhD,1 Mats Heyman, MD, PhD,3 Jukka Kanerva, MD, PhD,4
Arja Harila-Saari, MD, PhD,5 Henrik Hasle, MD, PhD,6 Stefan So¨derha¨ll, MD, PhD,3 O´lafur Gisli Jo´nsson, MD,7
Stian Lydersen, PhD,8 and Kjeld Schmiegelow, MD, PhD2,9 On behalf of the Nordic Society of Paediatric
Haematology and Oncology (NOPHO)
Background. In spite of major improvements in the cure rate of
childhood acute lymphoblastic leukaemia (ALL), 2–4% of patients
still die from treatment related complications. Procedure. We inves-
tigated the pattern of treatment related deaths (TRDs) and possible
risk factors in the NOPHO ALL-92 and ALL-2000 protocols. Fifty-
ﬁve TRDs were identiﬁed among the 1,645 ALL-92 patients and 33
among the 1,090ALL-2000 patients.Results. Therewas no signiﬁcant
difference in the incidence of TRDs between the two protocols (3.4%
vs. 3.2%). Five patients died before initiation of therapy (0.2%), and
the overall subsequent risk of induction death and death in ﬁrst com-
plete remission (CR1) was 1.2% and 1.8%, respectively. Infections
were the major cause of death comprising 72% of all cases including
9 deaths from Pseudomonas aeruginosa and 11 deaths from fungal
infections. Other causes of death included bleeding or thrombosis
(eight patients), tumour burden related toxicities (seven patients) and
organ toxicity (seven patients). Female gender (hazard ratio (HR): 2.2,
95% conﬁdence interval (95% CI): 1.4–3.4), high white blood cell
count (≥200× 109/L) at diagnosis (HR: 3.5, 95% CI: 1.7–7.1), T-cell
disease (HR: 1.9, 95% CI: 1.01–3.7), Down syndrome (HR: 7.3, 95%
CI: 3.6–14.9) and haematopoietic stem cell transplantation in CR1
(HR: 8.0, 95% CI: 3.3–19.5) were identiﬁed as independent risk fac-
tors for TRD. Conclusion. Several TRDs were potentially preventable
and future efforts should be directed towards patients at risk. Pediatr
Blood Cancer. 2011;56:551–559. © 2010 Wiley-Liss, Inc.
Key words: acute lymphoblastic leukaemia; paediatric oncology; risk factors; toxicity; treatment-related death
INTRODUCTION
Improved risk grouping and intensiﬁcation of chemotherapy
have signiﬁcantly reduced the relapse rate of childhood acute lym-
phoblastic leukaemia (ALL) [1–3]. In contrast, and in spite of
improved supportive care, treatment related deaths (TRDs) continue
to occur in 2–4% of the patients (Table I) [4–11]. Thus, the relative
signiﬁcance of TRDs among all events has increased because of the
decreasing relapse-rate in current treatment protocols. TRD repre-
sents the ‘tip of the iceberg’ of the total toxicity related to modern
treatment of childhood ALL.
Infections, bleeding or thrombosis, tumour burden complica-
tions, and therapy induced organ toxicities are the most common
causes of TRD [4,7,12,13]. Four major factors inﬂuence the risk of
these and other severe, although non-fatal, toxicities: the leukaemia
itself (e.g., the tumour burden and speciﬁc organ involvement), the
treatment intensity, the supportive care (including speciﬁc guide-
lines and physician and patient compliance to these) and host factors
(including inherited genetic polymorphisms that inﬂuence drug dis-
position and immune function) [2,14–16].
To identify potentially preventable risk factors for speciﬁcTRDs,
we explored all 88 TRDs among 2,735 ALL patients treated on two
consecutive Nordic protocols from 1992 to 2008.
MATERIALS AND METHODS
Since 1992 all children with ALL in the ﬁve Nordic countries
(Denmark, Finland, Iceland,Norway andSweden) have been treated
according to common Nordic protocols [1]. Long-term results have
recently been published for the NOPHO ALL-92 study showing
a 10-year event-free survival (EFS) of 74.6± 1.1% and an overall
survival of 84.7± 0.9%. For theNOPHOALL-2000 protocol, the 5-
year EFSwas 79.4± 1.5% and the overall survival was 89.1± 1.1%
[17]. Between January 1992 and June 2008, 2,882 children 1.0–14.9
years of age with B-cell precursor or T-cell ALL were diagnosed
within the Nordic countries. We excluded the following patients
from this study: 2 Down syndrome patients who received no anti-
leukaemic therapy (1 with signiﬁcant co-morbidity and 1 diagnosed
post-mortem), 14 patients not treated according to NOPHO ALL-
92 or ALL-2000 protocols, 41 patients treated according to the
NOPHO ALL-2000 protocol before it was ofﬁcially opened, 20
patients treated according to the international protocol for Ph+
(t(9;22)(q34;q11)/BCR-ABL fusion) ALL, 14 patients who were
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e. diagnosed and started on anti-leukaemic therapy outside the Nordic
countries, 52 patients who changed protocol during therapy (from
ALL-92 to ALL-2000, or from ALL-2000 to ALL-2008), 1 patient
who died from Leighs encephalopathy day 6 during induction ther-
apy and three patientswith bilineage leukaemia.Thus, 2,735patients
were included in the present study (Fig. 1). Patients with resistant
disease to NOPHO treatment were included until the day resistant
disease was recognised. Patients dying from a second malignant
neoplasm or after relapse were not considered as TRD in this study.
Since the purpose of this studywas to explore the risk of TRDamong
children 1.0–14.9 years of age in order to improve the treatment
and supportive care for non-infants and non-Ph+ALL patients, we
excluded patients treated according to other protocols, including
the international Interfant and EsPhALL protocols. Of the 1,231
females and 1,504 males, 1,645 patients were treated according
to the NOPHO ALL-92 protocol (open from January 1992 until
October 2001), and 1,090 patients were treated according to the
NOPHO ALL-2000 protocol (open from January 2002 until June
2008). There were 2,431 (89%) B-cell precursor and 277 (10%)
T-cell ALL patients (no information on lineage was available for
27 patients). Fifty-nine had Down syndrome and 68 patients were
registeredwith CNS leukaemia at diagnosis. Nine hundred and ﬁfty-
ﬁve (35%) were standard risk, 942 (34%) intermediate risk and
838 (31%) were high-risk patients according to the ALL-92 and
ALL-2000 criteria. Patients who stayed in ﬁrst complete remission
(CR1) were followed until April 2009. Data were obtained from
the prospective registration of all patients in the NOPHO leukaemia
registry. Additional clinical data concerning cause of death from the
patient ﬁles for the 88 TRDs were obtained through a questionnaire
sent out to the treating centres. Fifty-ﬁve of the 88 TRDs in this
study have previously been published [12].
Risk Grouping
Patients were stratiﬁed into three risk groups: standard risk
(SR), intermediate risk (IR) and high-risk (HR) ALL. In this
study, SR and IR ALL are combined as low-risk ALL. Stratiﬁ-
cation criteria for the low-risk groups were (all criteria needed):
WBC <50.0× 109/L, B-cell precursor ALL, no CNS or tes-
ticular leukaemia, no unfavourable cytogenetic alterations (i.e.
11q23/MLL-rearrangements, t(9;22)(q34;q11)/BCR-ABL fusion,
t(1;19)(q23;p13)/E2A-PBX1 fusion, hypodiploidy (<45 chromo-
somes)), and good response to initial therapy deﬁned as M1 or M2
bone marrow at day 15 and M1 bone marrow at day 29. The HR
patients fulﬁlled at least one of the high-risk criteria listed above.
In the ALL-2000 protocol, HR patients with at least one of the
following criteria were allocated to haematopoietic stem cell trans-
plantation (HSCT) in CR1:M3 bonemarrow on day 29, 11q23/MLL
rearrangements and age ≥10 years, t(9;22)(q34;q11)/BCR-ABL
fusion, a karyotype with a modal chromosome number <34, or
initial WBC ≥200× 109/L. There were no uniform Nordic criteria
for HSCT in the ALL-92 protocol.
Induction Remission Treatment, Both Protocols
The ﬁrst 50 days of therapy included only small differences
between the two protocols and consisted of the following: induc-
tion included prednisolone (60mg/m2/day) day 1–36 followed by
10 days tapering. Pre-treatment for 1–6 days with prednisolone dose
increments was used in cases with large leukaemic cell burden at
Pediatr Blood Cancer DOI 10.1002/pbc
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Fig. 1. Flow chart of patients included in the study.
diagnosis to decrease the risk of tumour lysis syndrome (TLS). Vin-
cristine (Vcr) was given weekly for 6 weeks in doses of 2.0mg/m2;
the maximum dose was increased from 2.0mg in the ALL-92 pro-
tocol to 2.5mg in the ALL-2000 protocol. In the ALL-92 protocol
doxorubicin at doses of 40mg/m2 was given three and four times
in the low-risk and high-risk groups, respectively. In the ALL-2000
protocol the corresponding number was reduced to two or three
doses for the low- and high-risk groups, respectively. Methotrex-
ate (MTX) was given intrathecally (i.t.) at days 1, 8, 15 and 29 in
age-adjusted doses. For the ALL-92 patients Erwinia asparaginase
was used (dose: 30,000 IU/m2 daily on days 37–46), and for the
ALL-2000 patients, Escherichia coli asparaginase was used (dose:
6,500 IU/m2 at 3- to 4-day intervals up to a total of four doses starting
treatment day 36).
Further Treatment
NOPHO ALL-92 protocol: Detailed information concerning
therapy for the NOPHOALL-92 protocol has been published earlier
[1,18]. Treatment duration from the day of diagnosis was 2.5 years
for the SR group and 2.0 years for the other groups. There were no
speciﬁc guidelines for supportive care in the ALL-92 protocol.
NOPHO ALL-2000 protocol: Following induction, the low-risk
groups received identical consolidation therapy consisting of 6-
MP (25mg/m2/day) and alternating blocks with high-dose MTX
(5 g/m2/24 hr with i.t. MTX and Leucovorin rescue) and low-dose
cytarabine (75mg/m2/day for 4 days, two times). After induc-
tion, early intensiﬁcation therapy followed for the high-risk groups,
which included two doses of cyclophosphamide (1,000mg/m2) 4
weeks apart with low-dose cytarabine (75mg/m2 daily for two 4
days periods), oral 6-thioguanine (6-TG) and two doses of i.t. MTX.
Consolidation therapy for the high-risk groups included alternating
courses of high-doseMTX (8 g/m2/24 hr with i.t. MTX and Leucov-
orin rescue) and high-dose cytarabine (12 g/m2) times two or four,
with two 2 months intervening periods of oral weekly MTX and
daily 6-MP with two Vcr/prednisolone reinductions per period. In
the low-risk groups the interval between high-dose MTX courses
was increased from 2 to 4 weeks compared to the ALL-92 pro-
tocol, and the start of Leucovorin rescue was delayed 6 hours to
“hour 42” from start of the MTX infusion. Patients with IR- or
HR-ALL received delayed intensiﬁcation therapy with dexametha-
sone (doses: IR patients 6mg/m2/day, HR patients 10mg/m2/day)
for 2 weeks, weekly Vcr (2.0mg/m2) for 4 weeks, weekly doxoru-
bicin (HR) or daunorubicin (IR), at a dose of 30mg/m2/day, three
(HR) or four (IR) times. In addition, E. coli asparaginase (dose:
6,500 IU/m2) was given four times followed by cyclophosphamide
(dose: 1,000mg/m2), low-dose cytarabine and 6-TG. Maintenance
therapy consisted of weekly oral MTX (starting dose: 20mg/m2)
and daily oral 6-MP, dose adjusted according to TPMT activ-
ity (starting doses, wild-type patients: 75mg/m2/day, heterozygous
patients: 50mg/m2/day, TPMTdeﬁcient patients: 5–10mg/m2/day).
In addition, low-risk patients received alternate pulses at four-week
intervals Vcr (2.0mg/m2, one dose)/dexamethasone (6mg/m2/day
for 5 days) and high-dose MTX (5 g/m2/24 hr) times ﬁve during the
ﬁrst year of maintenance therapy. HR patients received reinductions
every four weeks throughout maintenance therapy consisting of Vcr
(2.0mg/m2) and dexamethasone (6mg/m2/day for 5 days). After 1
year inmaintenance patients in the low-risk groupswere randomised
into two arms: one arm with only 6-MP/MTX, and one arm with
6-MP/MTX plus an additional eight pulses every 6weeks of dexam-
ethasone (dose: orally 6mg/m2/day) and Vcr (dose: i.v. 2.0mg/m2,
max. dose 2.5mg) for 5 days. For HR patients who were not treated
with HSCT in CR1, two cycles of the LSA2L2 regimen [19] was
inserted at the beginning of maintenance therapy. Children above 5
years of age with T-cell ALL and mediastinal mass, and/or WBC at
diagnosis 100< 200× 109/L, and/or CNS leukaemia at diagnosis
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received cranial irradiation (24 or 18Gy depending on whether or
not CNS leukaemia was present at diagnosis). The treatment dura-
tion was 2.5 years for low-risk patients and 2.0 years for high-risk
patients.
The ALL-2000 protocol included guidelines for supportive care
concerning TLS, hyperleukocytosis, superior vena cava syndrome
and superior mediastinal syndrome. There were no general recom-
mendations for prevention of infection with Pneumocystis jiroveci
(PJ), fungal infections or management of febrile neutropenia. The
use of myeloid growth factors was optional after courses with high-
dose cytarabine (2 g/m2).
Causes of Death
The causes of death were grouped as (i) related to tumour burden
(i.e. TLS or leukostasis with compromised organ function due to
inﬁltrating blast cells), (ii) bleeding or thrombosis, (iii) infections,
(iv) therapy-induced organ toxicity and (v) other or uncertain cause.
The criteria for infectious deaths were clinical signs of infections
in combination with fever and/or raised C-reactive protein and/or
microbiologically proven infection, and no other obvious cause of
death. An autopsy was performed in 34 (39%) cases.
Statistical Analysis and Deﬁnitions
Proportions were compared by Chi-square tests. Kaplan–Meier
plots and survival tables were used for survival analysis includ-
ing estimation of cumulative incidence of TRD and subgroups
were compared using Log-rank tests. The main event in the anal-
ysis was TRD including (i) pre-treatment death (death before any
anti-leukaemic therapy), (ii) induction death (death after start of
treatment, but before achieved remission) and (iii) death in CR1
(included deaths happening up to 6 months after end of treatment).
Patients who experienced other events (resistant disease, relapse
or second malignant neoplasms) were censored at the time of these
events. Time to TRDwas deﬁned as time between diagnosis of ALL
and date of death. Patientswho experienced no eventswere censored
at the time of last follow-up. Cox proportional hazard regression
analysis was performed with time to TRD (or time to infectious
TRD) as only event, and the following covariateswere included: sex,
age (< or ≥10 years), WBC (< or ≥200× 109/L), B-cell precursor
versus T-cell disease, protocol (ALL-92 vs. ALL-2000), presence
or absence of CNS-disease, Down syndrome and HSCT in CR1.
Age was dichotomised at 10 years since this was used as stratiﬁca-
tion criteria for the intermediate risk group in both protocols. For
patients who underwent HSCT in CR1, a time-dependent covariate
was deﬁned as zero before, and one after the date of HSCT, and for
all other patients, this time-dependent covariate was deﬁned as zero.
We checked for the possible 10 two-way interactions among the 5
signiﬁcant covariates, using a stepwise approach with Bonferroni
adjusted signiﬁcance level 0.05/10= 0.005. In all other analyses,
P-values <0.05 were considered signiﬁcant. All tests were two-
sided. The statistical analyses were performed using the SPSS 16.0
statistical software.
Ethical Considerations
The protocols were approved by the national or regional ethics
committees in the ﬁve Nordic countries, and the study was con-
ducted in accordance with the Declaration of Helsinki.
RESULTS
Of the total of 2,735 patients, 51 females and 37 males (3.2%)
with a median age of 4 years (75%, range 2.0–11.0 years) at diag-
nosis experienced a TRD. The TRDs constituted 25% of all 354
deaths in the study population with 240 deaths after relapse as the
largest group. According to risk groups (stratiﬁcation based on up-
front criteria) the cumulative incidence of TRD was 1.7± 0.4%,
2.4± 0.5% and 6.7± 0.9% for the SR, IR and HR group, respec-
tively (P< 0.001).Of all patients, ﬁvedeaths (0.2%)occurredbefore
initiation of treatment (pre-treatment deaths), 34 deaths (1.2%)
occurred during remission induction and 49 deaths (1.8%) happened
during post-induction treatment in CR1 including 10 deaths after
HSCT (Fig. 1). Of the 88 TRDs, 63 (72%) patients died from infec-
tions, 8 (9%) died from bleeding or thrombosis, 7 (8%) died from
organ toxicity and 7 (8%) died from tumour burden complications.
In addition, two HSCT patients died from severe graft-versus-host
disease (GVHD) of which one of them had additional respiratory
failure, and one patient died from an erroneous procedure (intrathe-
cal injection of Vcr). The cumulative incidence of TRD in the
ALL-92 and ALL-2000 protocol did not differ signiﬁcantly, and
was 3.4± 0.5% and 3.2± 0.6%, respectively (P= 0.85).
Tumour Burden Related Early Deaths
Of the seven patients (six boys) who died from tumour burden
related problems (of which ﬁve died pre-treatment), six patients
had a WBC ≥350× 109/L at diagnosis. All, except one patient,
died from intracerebral inﬁltration of leukaemic blast cells with or
without intracerebral bleeding. One patient with a large mediastinal
tumour (WBC at diagnosis: 23× 109/L) was resuscitated because
of cardiac arrest during anaesthesia for diagnostic bone marrow
aspiration and died after 11 days due to secondary brain damage.
No patients died from TLS complications.
Treatment Related Death in Relation to Time and Phase
of Therapy
The TRDs occurred at a median of 6 weeks from diagnosis (Fig.
2) and 76% of the non-HSCT related deaths occurred within the
ﬁrst 80 days of treatment. The annual proportion of TRD before
remission (pre-treatment deaths and induction deaths) ranged from
0.0–2.7% (calendar years 1992–2007). Of the 2,730 patients who
started anti-leukaemic treatment, 34 patients died during remis-
sion induction (Fig. 1) yielding a proportion of induction death of
1.2% (0.7% in the low-risk groups and 2.4% in the high-risk group,
P< 0.001). The causes of induction deaths were infections (n= 26),
tumour burden (n= 2) and bleeding or thrombosis (n= 6).
Of the 2,669 patients who achieved remission, 49 died in CR1
(including 10 post-HSCT patients) giving a proportion of death in
CR1 of 1.8% (1.3% in the low-risk groups and 3.2% in the high-
risk group, P= 0.001). Of these, 17 died during the last part of the
induction phase, 3 died during early intensiﬁcation, 2 during consol-
idation, 3 during late intensiﬁcation, 12 during maintenance (none
of which during the LSA2L2 regimen) and 1 during cranial irradia-
tion. For one patient, exact information concerning treatment phase
was lacking. Of the 12 patients who died during maintenance, only
2 infectious TRDs occurred within 6 weeks from administration of
pulses ofVcr/dexamethasone.Of the 39 non-HSCTTRDs, 30 (77%)
patients died from infections and6 (15%) fromorgan toxicity includ-
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Fig. 2. Causes of death in relation to time from diagnosis for 85 out of
88 treatment related deaths (TRDs) in theNOPHOALL-92 andNOPHO
ALL-2000 protocol (TRDs post-HSCT included). Not shown are one
patient who died from an accidental intrathecal injection of vincristine,
and two post-haematopoietic stem cell transplantation patients who died
from severe GVHD. F: Female (n= 1,231). M: Male (n= 1,504).
ing two deaths from acute pancreatitis after the second and third
dose of asparaginase, respectively. Other deaths from organ toxicity
included one MTX-related and one hypertensive encephalopathy,
one toxic hepatitis following a high-dose MTX course and one
patient who died shortly after cessation of therapy of haemolytic
uremic syndrome of unknown origin. One patient died 6 weeks after
diagnosis from an intestinal bleeding, one Down syndrome patient
died after 10 months from an intracerebral bleeding and one patient
died after an erroneously administered intrathecal dose of Vcr.
Of the 110 patients who underwent HSCT in CR1, 10 patients
died from treatment related complications; 5 died from infections,
1 from leukoencephalopathy and 2 from GVHD. In two HSCT
patients who died, CMV infection was suspected, but not proven.
Infectious Deaths
Of the 63 infectious deaths (Table III), 7 cases were polybac-
terial or polymicrobial, and in 16 cases no microorganism was
found. Chemotherapy induced neutropenia (deﬁned as neutrophils
≤0.5× 109/L) during the last week of life was found in relation to
29 (48%) of the infectious deaths.
Bleeding and Thrombosis
Of the eight TRDs caused by bleeding or thrombosis
(leukostasis-associated TRDs excluded), six deaths occurred within
the ﬁrst 50 days from diagnosis including four patients who died
before the ﬁrst dose of asparaginase. Of the bleeding deaths, two of
the haemorrhages were located to the brain, one to the intestines and
one haemorrhage was diffuse involving multiple organs. Of the four
who died from thrombosis/infarction, three occurred in the brain
and one in the intestines.
Risk Factors
In simple Cox regression analyses several closely associated
clinical features were linked to an increased risk of TRDs: T-cell
disease, WBC ≥200× 109/L at diagnosis, presence of CNS disease
and HSCT in CR1 (Table II). Kaplan–Meier plot for WBC is shown
in Figure 3. In multiple Cox regression analysis, female gender,
WBC ≥200× 109/L at diagnosis, T-cell disease, Down syndrome,
and HSCT in CR1 were identiﬁed as independent risk factors for
TABLE II. Risk Factors for Treatment Related Death (TRD), NOPHO ALL-1992 and NOPHO ALL-2000 Protocol
Risk factors TRD (n= 88) All patients (n= 2735) HR (95% CI), simple regression Adjusted HR (95% CI), multiple regression
Sex
Female 51 1,231 1.7 (1.1–2.6) 2.2 (1.4–3.4)
Male 37 1,504 1.0 1.0
Age (years)
1–9 71 2,274 1.0 1.0
10–14 17 461 1.2 (0.7–2.1) 0.9 (0.51–1.5)
WBC (×109/L)
<200 69 2,603 1.0 1.0
≥200 19 132 6.5 (3.9–10.8) 3.5 (1.7–7.1)
Immunophenotype
T-cell 22 277 3.2 (2.0–5.3) 1.9 (1.01–3.7)
Not T-cell 66 2,458 1.0 1.0
Protocol
1992 55 1,645 1.0 (0.7–1.6) 1.2 (0.76–1.8)
2000 33 1,090 1.0 1.0
Down syndrome
Yes 9 59 5.6 (2.8–11.2) 7.3 (3.6–14.9)
No 79 2,676 1.0 1.0
CNS
Yes 7 68 3.8 (1.7–8.2) 2.1 (0.93–4.6)
No 81 2667 1.0 1.0
HSCT in CR1
Yes 10 109 17.7 (8.1–38.6) 8.0 (3.3–19.5)
No 78 2,626 1.0 1.0
HR= hazard ratio; 95% CI= 95% conﬁdence interval; WBC=white blood cell count at diagnosis; HSCT in CR1= haematopoietic stem cell
transplantation in ﬁrst complete remission. A time-dependent covariate was constructed for HSCT patients (see text).
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TABLE III. Causative Organisms in the 63 Infectious Deaths in the NOPHO ALL-1992 and ALL-2000 Protocol
Number of patients
Major group Organism ALL-1992 ALL-2000
Bacteria Coagulase negative staphylococcus 1
Bacillus cereusa 1
Pseudomonas aeruginosa† 8 1
Eschericia coli 3 1
Klebsiella 1
Listeriaa 1
Stenotrophomonas (Xanthomonas) maltophilia 1
Enterobacter 1
Stomatococcus 1
Micrococcus 1
Unspeciﬁed 2
Virus Cytomegalovirus** 1 2
Adenovirus 1
Inﬂuenza B 1
Respiratory syncytial virus 1
Fungi Candida* 2 3
Geotrichum capitatum 1
Pneumocystis jirovechi 1
Unspeciﬁed† 3 1
Polybacterial or microbial**,† 6 1
Unspeciﬁed microorganism**,†† 9 7
Total 41 22
The number of daggers indicate the number of Down syndrome cases (n= 5) in respective groups. The number of asterisks indicate the number
of deaths in respective groups post-haematopoietic stem cell transplantation (HSCT) (n= 7). aCentral nervous system infections (n= 2).
Fig. 3. Cumulative incidence of treatment related death (TRD) by
white blood cell count at diagnosis (WBC). Patients with WBC
<200× 109/L (2.5± 0.3% (standard error)) versus patients with WBC
≥200× 109/L (13.0± 3.6%) at diagnosis (Kaplan–Meier estimator,
P< 0.001, Log-rank test). Patients who underwent HSCT in CR1 were
censored at the time of HSCT.
TRD (Table II). The only signiﬁcant interaction was Down syn-
drome and WBC ≥200× 109/L (P< 0.001), where the presence of
both these factors attenuated the hazard. However, this did not sig-
niﬁcantly affect the effects of the other risk factors in Table II. The
haemoglobin level at diagnosis was not found to be a risk factor for
TRD. Analysing infectious TRDs separately, females more often
died from infections compared to males (adjusted HR: 2.4, 95% CI:
1.4–4.0). Of the nine Down syndrome TRDs, seven occurred before
achieved remission.
DISCUSSION
Despite a steady improvement in supportive care over the last
30 years, treatment related toxicity remains a major challenge in
childhood ALL therapy, and the risk of treatment related mortal-
ity has not decreased substantially in the last 20 years [4,7,12,20].
Furthermore, in parallel to the decreasing number of patients dying
from the leukaemia itself (i.e. tumour burden related death, resistant
disease and relapse), TRDs comprise an increasing proportion of the
overall mortality (25% in our study). In addition, TRD represents
the most severe form of overall treatment related toxicity, and pre-
ventive efforts directed towards factors inﬂuencing TRD will also
affect toxicity in general.
The TRDs can be subdivided into infections, tumour burden
complications, organ toxicity and bleeding/thrombosis with infec-
tions as the most frequent cause. To reduce toxicity and prevent
TRD, interventions are needed to address the risk factors, that is the
tumour burden, the treatment intensity and the supportive care. In
addition, there is a need of increased knowledge of relevant genetic
host factors.
Concerning the seven deaths from tumour burden related prob-
lems within the ﬁrst days from diagnosis, the outcome for patients
like these is clearly related to the rapidity of the diagnostic work-up
and initiation of therapy. Traditionally, patients with a high tumour
burden have been treatedwith intravenous alkaline ﬂuids, a xanthine
oxidase inhibitor (allopurinol), and gradually increasing doses of a
corticosteroid, delayingmore intensive chemotherapy until the blast
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count has fallen and thereby lowering the risk of TLS.Modern treat-
ment with recombinant urate oxidase (rasburicase) has been shown
to be safe and effective for prophylaxis or treatment of the urate
related problems of TLS in childhood malignancies [21]. Rasburi-
case produces a rapid decrease in plasma uric acid concentration
and makes it possible to start with tumour reducing therapy within
hours [21,22]. Since a mononuclear white blood cell count above
200 is virtually pathognomonic for leukaemia, rapid initiation of
full dose corticosteroid therapy should be considered after admin-
istration of urate oxidase at the presentation of such patients and
sampling of peripheral blood for the diagnostic leukaemia work-up.
This approach could potentially prevent the tumour burden related
TRDs seen in this study. In case of signiﬁcant electrolyte distur-
bances, for example hyperphosphatemia, these should be corrected
before start of anti-leukaemic therapy.
The treatment-induced immunosuppression includes neutrope-
nia, impaired humoral antibody response, impaired cell-mediated
immunity, phagocytic defects and disturbed cytokine function
[23,24]. Furthermore, Eyrich et al. [25] recently showed that B-
cells were most severely affected throughout therapy and did not
recover before the end of therapy. T-cells and natural killer cells
partially recovered at the end of induction therapy and are the dom-
inating lymphocyte subset during maintenance therapy. We have
shown that infections remain the most common cause of TRD com-
prising 72% of all cases, which is in line with the ﬁndings of most
other groups [4,9,13,26].
It is noteworthy that 76% of all TRDs occurred during the ﬁrst 80
days of treatment when the immune deﬁciency is most pronounced
due to the tumour load itself (i.e. inﬁltrating blast cells in bone
marrowand other lymphoid tissue) and very intensive chemotherapy
including corticosteroids.
Of the patients dying from infections, 48% had chemotherapy-
induced neutropenia during the week preceding death. However,
the choice of empirical anti-microbial therapy for febrile neutrope-
nia varies widely between treating centres even within the same
collaborative group. In a British survey of 21 United KingdomChil-
dren’s Cancer Study Group (UKCCSG) centres treating children
with febrile neutropenia, the management varied both concerning
the deﬁnition of fever, the deﬁnition of neutropenia, and in the
choice of empirical antibiotic therapy [27]. Studies have shown
that combination therapy of a Pseudomonas-covering beta-lactam
(e.g. ceftazidime) and an aminoglycoside is superior tomonotherapy
in case of Pseudomonas infections [28,29]. Out of the nine Pseu-
domonas TRDs in our study, only one occurred in the ALL-2000
protocol. A likely explanation for this is an increased use of empiric
Pseudomonas-covering antibiotic therapy in case of febrile neu-
tropenia, but no data on routine supportive care have been registered
as part of this study.
There was no uniform approach to PJ infection prophylaxis dur-
ing the study period and no patient-speciﬁc data on the use of
PJ-prophylaxis is available. Thus, it is unknown to what extent local
strategies for PJ-prophylaxis have contributed to the low frequency
of mortality from PJ (Table III).
Concerning antibacterial prophylaxis, there is no uniform
approach in the Nordic region. The use of prophylactic TMP-
SMX has earlier been shown to reduce the incidence of both PCP
infections and other infections and bacteraemia in ALL patients
[30,31]. A retrospective Danish study comparing two different
patients groups, one receivingTMP-SMXprophylaxis during induc-
tion treatment, and one without, showed that the TMP-SMX group
had signiﬁcantly fewer episodes of fever and fewer fever-related
positive blood cultures during induction therapy [32]. In a review
article on efﬁcacy of oral prophylactic antibiotics in neutropenic
afebrile oncology patients (including 22 clinical trials) van deWeter-
ing et al. [33] concluded that oral prophylactic antibiotics decreased
Gram-negative bacteraemia and infection related mortality. How-
ever, only 3 of the 22 reviewed trials included paediatric patients.
Larger prospective studies are needed to explore if antibacterial
prophylaxis during the neutropenic phases of the ﬁrst 3 months of
anti-leukaemic therapy can reduce the risk of TRDs in childhood
ALL.
Of the 11 deaths due to fungal infections, 9 occurred within the
ﬁrst 9 weeks of treatment. Early death from fungal infections has
also been found by others [7], pointing at the potential advantage
of anti-fungal antibiotic prophylaxis at least during the early part
of treatment. One possible disadvantage when using azoles as anti-
fungal prophylaxis in combination with weekly administration of
Vcr (as during induction therapy) is increased Vcr-related neurotox-
icity. Vcr is metabolised by CYP3A enzymes and azoles are potent
inhibitors of CYP3A isoenzymes resulting in higher Vcr concentra-
tions [34,35]. Fluconazole is a relativelyweaker inhibitor of CYP3A
compared to other azoles (e.g. itraconazole) [35] leaving ﬂucona-
zole as a reasonable drug of choice, although it has a limited effect
on invasive aspergillosis and ﬂuconazole-resistant candida strains
[36,37]. In the British UKCCSG study on febrile neutropenia, the
strategy for empirical anti-fungal treatment was not described in
detail [27], and further studies are needed to address this issue.
Some of the patients in our study died of infections despite
seemingly adequate antibiotic treatment according to the resistance
pattern of the microorganism in question. This raises the question
of the role of critical host factors including pharmacogenetics and
immunogenetics. Studies on genetic polymorphisms in immunoreg-
ulating mediators have shown an association with outcome during
childhood leukaemia induction therapy [14], in childhood AML
patients [38], in childhood malignancies in general [16] and in post-
HSCT patients [39,40]. However, most studies are candidate gene
based involving only a few genes, and genome-wide studies of vari-
ations within the immune response involving multiple genes and
haplotypes are lacking. Identiﬁcation of possible immunogenetic
risk proﬁles at the start of therapy could potentially be helpful for
risk adapted and individualised supportive care. Possible preventive
measures for patients at signiﬁcantly increased risk of infectious
TRD could include: (i) reduced or modiﬁed anti-leukaemic therapy
intensity, (ii) prophylactic antibiotic therapy, (iii) immunological
reconstitution (e.g. immunoglobuline substitution) and (iv) granu-
locyte colony-stimulating factor therapy.
Subgroups of patients dying from speciﬁc organ toxicities
(bleeding or thrombosis included) constitute a relatively small frac-
tion of TRDs. The two deaths from asparaginase induced acute
pancreatitis are rare events and most patients experiencing acute
pancreatitis during treatment are successfully treated [41]. Another
frequent complication from asparaginase treatment is thrombotic
events occurring in up to 36% of patients [42]. In our study, the
only patient possibly dying from an asparaginase related throm-
botic event was a Down syndrome patient who died on treatment
day 50 from a thrombosis in the right common carotid artery
resulting in massive cerebral infarction. Of the four patients who
died from bleeding complications (tumour burden associated bleed-
ings excluded), three had accompanying severe thrombocytopenia
(platelets <20× 109/L). Three of the patients also had an ongoing
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infection, illustrating the additive risk of infection and coagula-
tion disturbances. Very large, probably international, genetic studies
such as those performed by the Ponte di Legno group (see Biondi et
al. [43]) are needed to identify patients at excessive risk of very rare
fatal events such as MTX-induced encephalopathy and liver failure.
In conclusion, TRD remains a major challenge and constitutes
an increasing fraction of all deaths in childhood ALL. Accord-
ingly, studies addressing the prevention of TRDs have become as
important as efforts to overcome the resistance to the anti-leukaemic
therapy.
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